Identification of therapeutic targets for bipolar disorder
A novel method using BK channel agonists in genetically modified animals exposed to stressors effectively treats bipolar disorder by targeting the CaV1.2-BK interaction, addressing treatment resistance and reducing suicide risk.
Patent Information
- Application Number
- JP2026524623
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-10-26
- Filing Date
- 2024-10-25
- Publication Date
- 2026-11-09
AI Technical Summary
Current pharmacological treatments for bipolar disorder are largely based on serendipitously discovered compounds, with many patients not responding, leading to high economic burden and increased suicide rates, and the biological mechanisms of the disorder remain unclear.
A method involving genetically modified animals with BK channel haploinsufficiency, exposed to mild stressors like sleep deprivation, to evaluate therapeutic efficacy, combined with administering BK channel agonists such as unoprostone or NS1619 to treat bipolar disorder, targeting the attenuation of protein-protein interaction between CaV1.2 and BK channels.
The method identifies effective therapeutic agents for both lithium responders and non-responders, reducing the economic burden and suicide risk by rescuing cellular-level deficiencies in calcium signaling, thereby stabilizing mood swings.
Smart Images

Figure 2026537430000001_ABST
Abstract
Description
Technical Field
[0001] (Cross-Reference to Related Applications) This application claims the benefit of priority of U.S. Provisional Application No. 63 / 545,880, filed on October 26, 2023, under 35 U.S.C. § 119(e) of the United States Patent Act. The entire content of the prior application is incorporated herein by reference in its entirety.
[0002] (Technical Field) The present disclosure relates generally to the identification of therapeutic targets, and more specifically to methods for evaluating the effectiveness of therapeutic targets for the treatment of bipolar disorder.
Background Art
[0003] Bipolar disorder (BP) is a severe psychiatric disorder in which episodes of depressive and manic states potentially appear periodically. The onset of this disease often occurs in young adulthood and leads to chronic disability. According to epidemiological data, the lifetime prevalence of BP in the United States is 4 to 5%. The estimated total annual national economic burden exceeds 195 billion dollars, of which approximately 25% is attributed to direct medical costs. At present, pharmacological treatments for BP are based on serendipitously discovered compounds. A considerable number of patients tend not to respond to treatment (for example, about half of BP patients do not respond to lithium, the first-line drug). At least 15 to 20% of BP patients eventually die by suicide. There is evidence that the suicide rate of BP patients is 20 to 30 times that of the general population. The direct and indirect costs related to suicide in BP patients are estimated to be 190 million dollars and 7.8 billion dollars, respectively.
[0004] Nevertheless, the biological mechanisms of BP have not yet been elucidated. Recent psychiatric genetics studies have shown that intracellular calcium (Ca 2+)It has been clarified that a group of genes involved in signal transduction underlie the risk of this disease. A considerable number of BP patients tend not to respond to treatment (for example, about half of BP patients do not respond to lithium, the first-line drug). If targeted therapeutic agents are discovered and developed based on the present disclosure, the therapeutic agents may be effective not only for lithium responders but also for lithium non-responders. As described above, the estimated total annual national economic burden exceeds 195 billion dollars, of which about 25% is attributable to direct medical costs. At least 15 to 20% of BP patients eventually die by suicide. There is evidence that the suicide rate of BP patients is 20 to 30 times that of the general population. The direct and indirect costs related to suicide in BP patients are estimated to be 190 million dollars and 7.8 billion dollars, respectively. Considering that blocking the manic-depressive cycle in BP can lead to a better prognosis, targeted therapeutic agents that can be identified using the models and methods of the present disclosure are also considered to contribute to a significant reduction in BP-related suicides. The present disclosure addresses the need for a mechanistic understanding of biological pathways associated with BP and enables advances in BP drug discovery. [Summary of the Invention]
[0005] In one aspect, the present disclosure provides a method for evaluating the effectiveness of a composition in the treatment of bipolar disorder, the method comprising providing a genetically modified non-human animal, e.g., a rodent, that exhibits haploinsufficiency of the big potassium (BK) channel, administering the composition to the genetically modified non-human animal, exposing the genetically modified non-human animal to a mild stressor, and determining whether the genetically modified non-human animal experiences a behavioral shift. In one aspect, the rodent animal is a mouse or a rat.
[0006] In one aspect, the mild stressor is short-term sleep deprivation (SD).
[0007] In one aspect, the method further comprises the step of subjecting the genetically modified non-human animal to a forced swim test (FST) before and after exposing the non-human animal to the mild stressor.
[0008] In one embodiment, the present disclosure provides a method for treating bipolar disorder, comprising administering a therapeutically effective dose of a BK channel agonist to a subject in need of treatment for bipolar disorder.
[0009] In one embodiment, the BK channel agonist includes unoprostone, unoprostone derivatives, NS1619, benzimidazolone derivatives or their derivatives, or combinations thereof.
[0010] In one embodiment, the subject is a lithium non-reactive individual.
[0011] In one embodiment, the disclosure provides a method for evaluating the mechanism of bipolar disorder in human-derived neurons, the mechanism being responsible for mood swings and the mechanism resulting in calcium signaling deficiency through attenuation of the protein-protein interaction between CaV1.2 and BK. [Brief explanation of the drawing]
[0012] The aspects, features, advantages and effects of the embodiments described herein will become apparent from the following description, the appended claims and drawings. [Figure 1] Figure 1A is a graph of time and calcium flux. Figure 1B is a graph of time to peak in induced neurons (iN cells) of healthy controls (HC) and patients with bipolar disorder (BP). Figure 1C is a graph of peak amplitude in HC and BP patients. Figure 1D is a graph of slope in HC and BP patients. Figure 1E is a graph of baseline [Ca2+]i in HC and BP patients. [Figure 2] This graph shows the correlation between the time to peak and the number of manic episodes in patients with BP (Behavioral Psychosis). [Figure 3]Figure 3A shows the detection of in situ proximity ligation assay (PLA) signals for co-localization of CaV1.2 and BK in iPSC-derived neurons. Figure 3B is a graph showing the significantly reduced CaV1.2-BK channel interaction in BP subjects compared to HC subjects. In contrast, Figure 3C shows that the expression levels of CaV1.2 (L-type voltage-gated calcium channel) and BK 1.1 (BK channel) themselves did not change. Figure 3D is a graph plotting these results. [Figure 4-1] Figure 4A is a bar graph showing that the delay in Ca2+ dynamics (delay in time to peak) in BP neurons was rescued by the BK channel agonists Uno and NS1619. Figure 4B shows individual data for Ca2+ dynamics (time to peak) in BP neurons. It shows slow Ca2+ dynamics and rescue by the BK channel agonist Uno in BP iPSC neurons. The control is the sum of records from two subjects. Each BP line is shown independently. Figure 4C shows the peak amplitude in BP neurons evaluated in Figure 4B. [Figure 4-2] Figure 4D is a bar graph showing that the BK channel agonist Uno rescued slow Ca2+ dynamics (delay in time to peak) in both lithium-responsive and non-responder-derived neurons. Lithium did not rescue cellular deficiencies in lithium-non-responder-derived cells, but only in lithium-responsive cells. [Figure 5-1] Figure 5A is a schematic diagram of the behavioral assay for fasting-to-stress (FST) with standardized sleep (SD). The experimental schedule for verifying phase transition is shown here. The numbers indicate the timing (weeks) of the assay and stressors. The arrows indicate the timing of sleep deprivation, the timing of FST administration in the preliminary experiment, and the timing of FST in the proposed experiment. Figure 5B shows the FST behavioral patterns. Total immobility time is shown for wild-type (WT) and BK heterozygous (Het) KO mice with and without administration of the BK channel agonist unoprostone (Uno). High immobility time was observed at 0 and 12 weeks in the preliminary experiment. [Figure 5-2]Figure 5C further shows that conditionally mPFC-specific BK Het KO mice [BK Het KO(mPFC)] exhibit behavioral phase shifts upon exposure to SD. [Figure 6] This image shows immunostaining of CaV1.2 and BK channels in nerve cells, and an example of immunofluorescence validation in BK KO Het mice. The image is a 40x magnification image of layer III of the mPFC region. [Figure 7] Figures 7A and 7B demonstrate that genetically CaMKIIα-specific BK Het knockout (COK) induces long-term behavioral phase shifts in mice upon exposure to SD (Simulated Depression). Figure 7A is a graph of total immobility time on day 1 of SD for genetically CaMKIIα-specific BK Het knockout mice (indicated by arrows) and WT mice. Figure 7B is a graph of total immobility time 5 weeks after SD exposure for genetically CaMKIIα-specific BK Het knockout mice (indicated by arrows) and WT mice. BK HET mice exhibit SD-induced behavioral phase shifts (a shift from more immobile to more active compared to WT mice). SD does not affect WT mice. 0 weeks: 5 indicates that the SD-induced shift state is maintained 1 week after SD (i.e., 5 weeks after baseline FST). 12 indicates that the FST behavior of BK HET mice returns to baseline (default state) 8 weeks after SD (i.e., 12 weeks after baseline FST). [Figure 8] This study demonstrates that repeated exposure of BK Het KO mice to SD after a normal rest period results in repeated behavioral phase shifts. [Figure 9] BK KO Het mice exhibit a dose-response effect on BK channels, and the behavioral phase shift in homozygous KO mice is more pronounced than in Het mice. [Figure 10] This immunofluorescence image shows that iN cells and iPSC-neurons express CaMKIIα and are glutamatergic / excitatory. [Figure 11] L-type voltage-gated calcium channels contribute to slow Ca2+ dynamics (Figure 11A), while membrane-bound or intracellular Ca2+ channel modulators do not (Figure 11B). [Figure 12]This shows that slow Ca2+ dynamics in BP iN cells were restored by the BK channel agonist Uno. [Figure 13] Figure 13(A, B) shows whole-cell patch-clamp current recordings from αCaMKII iN cells. Figure 13(C) shows representative data: BP iN cells show low outward current density (peak amplitude quantified after leak subtraction and normalized by cell volume). [Figure 14] This study shows no significant difference between the control and BP iPSC-neuronal cell cultures in terms of cortical marker staining. [Figure 15] The graph shows the decrease in BP spike frequency in MEA recordings (left graph) and recovery with the BK channel agonist Uno (right graph). The two controls are shown as a combined bar graph, and each BP line is shown independently. [Figure 16] Co-IP of CaV1.2-BK channels in a 3-month-old neural network derived from HC. The complex was immobilized on agarose with a CaV1.2 primary antibody, and Western blotting was performed using an anti-BK channel antibody. [Figure 17] This study shows that damage to the medial prefrontal cortex (mPFC) alters grooming frequency in the sucrose splash test. [Figure 18] BK KO mice showed significant changes in the forced swimming test (Figure 18A) and the sucrose splash test (Figure 18B), but showed no changes in the open field test (Figure 18C). [Figure 19-1] This study demonstrates the specificity of behavioral change in BK knockout (Het) mice. WT mice did not show behavioral change in the forced swimming test induced by short-term sleep deprivation (SD), a mild stressor. In contrast, BK KO mice showed longer periods of immobility (decreased activity) before SD (week 0), increased activity after SD (week 4), and returned to a decreased activity state after a long washout from SD (week 12) (Figure 19A). BK KO mice showed low activity before SD (decreased grooming frequency), increased activity after SD, and returned to a decreased activity state after a long washout from SD, but WT mice did not show behavioral change in the sucrose splash test (Figure 19B). [Figure 19-2] No differences were observed in the open-field test between BK and WT mice (Figure 19C). [Figure 20] This study reveals a novel mechanism underlying BP, namely the attenuation of the protein-protein interaction between VDCC / CaV1.2 and BK channels. EM is estramustin, and CaVC-pep is the C-terminal peptide of CaV1.2. [Figure 21-1] This diagram illustrates pharmacological interventions for BP-related Ca2+ signaling deficiencies. A schematic diagram of candidate selection is shown (Figure 21A). [Figure 21-2] Rescue of BP neurons by estramustin, which delays the time to the Ca2+ peak. Number of subjects: HC=3, BP=2, BP+EM=2. Number of cells: HC=37, BP=50, BP+EM=55 (Figure 21B). [Figure 22] This is a molecular manipulation to induce the BP phenotype in HC neurons. The molecular structure is CaV1.2 (Figure 22A, modified from Sutphin et al., Congenital Heart Disease, 2016). The CaV1.2 C-terminal peptide (CaVC-pep) significantly reduced the BK-CaV1.2 channel interaction as assessed by PLA. In this analysis, assuming that PLA data were unaffected by methodological changes, some missing data was estimated by integrating two methods (Figure 22B). CaVC-pep induced a delay in the time to peak, a major cellular phenotype of BP neurons, in HC neurons. Subject count: HC=3; HC+CaVC-pep=3; BP=2. Cell count: HC=37, HC+CaVC-pep=32; BP=31 (Figure 22C). [Figure 23] Case report of Uno as a combination therapy option. The graph below shows Ca2+ signaling data from iN cells derived from a patient with proline-rich transmembrane protein 2 (PRRT2) mutations and clinically presenting with bipolar disorder. Ctl represents iN cells from a healthy control, FAM0002 represents the patient, and the data is derived from the patient's iN cells; Olz (10 μM) represents FAM0002 iN cells administered olanzapine (10 μM) for 7 days; Olz + Uno (2 nM) represents FAM0002 iN cells administered these combination drugs for 7 days. [Modes for carrying out the invention]
[0013] Before describing in detail the compounds, compositions, and methods, it should be understood that this disclosure is not limited to the specific processes, compositions, or methodologies described, and that these may change. Furthermore, it should be understood that the terms used herein are for the purpose of describing specific versions or embodiments and are not intended to limit the scope of this disclosure, which is limited only by the appended claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art. While methods and materials similar to or equivalent to those described herein may be used in carrying out or testing embodiments of this disclosure, preferred methods, apparatus, and materials are described below.
[0014] Furthermore, it should be understood that certain features of the Disclosure described in the context of individual embodiments for clarity may also be provided in combination in a single embodiment. Conversely, various features of the Disclosure described in the context of a single embodiment for brevity may also be provided individually or in any suitable subcombination.
[0015] In this specification, the singular forms “a,” “an,” and “the” are to include the plural unless the context clearly indicates otherwise. Unless otherwise defined, all technical and scientific terms used herein are to have the same meaning as those generally understood by those skilled in the art. Nothing in this disclosure should be construed as acknowledging that the embodiments described herein do not have prior rights to the disclosure by prior art. In this specification, the term “comprising” means “including, but not limited to.”
[0016] In this specification, the term "about" means plus or minus up to 10% of the numerical value used. For example, "about 50%" means a range of 45 to 55%, including exactly 50%. The term "about" may also refer to plus or minus 1%, 5%, or 10% of the numerical value used.
[0017] "Administration," when used in combination with the compounds of this disclosure, means administering the compound directly into or onto a target tissue, or administering the compound systemically or topically to a patient or other subject.
[0018] As used herein, the terms “animal” or “subject” include, but are not limited to, humans and non-human vertebrates (wild animals, laboratory animals, livestock, farm animals, pets, etc.). As used herein, the terms “subject,” “individual,” and “patient” are interchangeable and refer to all animals, including mammals, mice, rats, other rodents, rabbits, dogs, cats, pigs, cattle, sheep, horses, primates, non-human primates, and humans.
[0019] The term “improve” means altering any of the characteristics and / or physical attributes of the tissue to which this disclosure is provided, applied, or administered. When used in conjunction with a disease condition, the term “improve” also means that when a disease condition is “improved,” the symptoms or physical characteristics associated with that disease condition are reduced, lessened, absent, delayed, or avoided.
[0020] The term “inhibit” includes blocking, avoiding, or restoring a particular outcome or process. With respect to treatment by administration of the compounds of this disclosure, “inhibit” includes partially or completely preventing the onset of symptoms, delaying their onset, reducing symptoms, or preventing, reducing, or eliminating a disease, condition, or disorder.
[0021] Unless otherwise specified herein, the term “active ingredient” refers to any compound of any formula described herein.
[0022] The term "pharmaceutically acceptable" refers to molecular entities and compositions that are generally considered safe and non-toxic. In particular, pharmaceutically acceptable carriers, diluents, or other excipients used in the pharmaceutical compositions of this disclosure are physiologically tolerable, compatible with other components, and do not typically cause allergic reactions or similar undesirable reactions (e.g., stomach discomfort, dizziness, etc.) when administered to a subject. In the embodiments herein, "pharmaceutically acceptable" means that it is approved by a federal or state regulatory authority or that its use in animals, particularly humans, is listed in the United States Pharmacopeia or other generally accepted pharmacopoeias. As used herein, the term "pharmaceutically acceptable salt" includes salts of the compounds of this disclosure that are safe and effective for use in mammals and possess the desired biological activity. pharmaceutically acceptable salts include salts of acidic or basic groups present in the compounds of this disclosure or compounds identified by the methods of this disclosure.
[0023] As used herein, the term “therapeutic” means an agent used to treat, counteract, improve, defend against, or protect against an undesirable condition or disease in a subject.
[0024] The “therapeutic effective dose” or “effective dose” of a compound (e.g., bapendavir) or composition in this disclosure means a predetermined amount in a reasonable benefit / risk ratio applicable to any medical procedure that produces a therapeutic effect on a subject receiving treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject exhibits or feels an effect, or a physician observes a change). Effects envisioned herein include, where appropriate, medical therapeutic effects. The specific dose of a compound administered in accordance with this disclosure will naturally be determined by the specific circumstances surrounding the case, including the compound administered, the route of administration, concomitant use of other active ingredients, the condition being treated, the activity of the particular compound used, the particular composition used, the subject’s age, weight, general condition, sex and diet, timing of administration, route of administration, excretion rate of the particular compound, and duration of treatment. The effective dose will be determined by a physician based on the above relevant factors and appropriate medical judgment. The therapeutically effective dose of the compounds disclosed herein is typically sufficient to achieve systemic or local effective concentrations in tissues when administered in a physiologically tolerable excipient composition.
[0025] As used herein, the terms “to treat,” “treated,” and “treatment” refer to a therapeutic action whose purpose is to obtain a beneficial or desirable clinical outcome, such as partially or completely defending against an undesirable physiological condition, disorder, or disease, delaying its progression (e.g., reducing or delaying the onset), or partially or completely restoring or suppressing the decline of a parameter, value, function, or outcome that has become abnormal or would become abnormal. For the purposes of this disclosure, beneficial or desirable clinical outcomes include relief of symptoms, reduction of the extent, vitality, or rate of progression of a condition, disorder, or disease, stabilization of a condition, disorder, or disease (i.e., no worsening), delaying the onset or suppressing the progression of a condition, disorder, or disease, improvement of a condition, disorder, or disease, or remission (partial or complete), which do not necessarily have to be directly related to immediate relief of clinical symptoms or enhancement or improvement of a condition, disorder, or disease. Treatment aims to elicit a clinically significant response, provided that the side effects are not excessive. Treatment also includes extending survival compared to no treatment.
[0026] The biological mechanisms of bipolar disorder (BP) remain unclear. Recent studies in psychogenetics suggest that, without being constrained by theory, intracellular calcium (Ca) may play a role. 2+ A series of genes involved in signal transduction have been identified as underlying the risk of this disease. This disclosure is Ca 2+ We investigated cells derived from BP patients, focusing on biological changes in signal transduction. This study identified several important factors to consider in BP treatment.
[0027] This disclosure study shows that BP patients, compared to a matched control group, showed a difference in Ca for neuronal activation. 2+ A delay in dynamics was observed. Figure 1A is a graph of time and calcium flux, and Figure 1B is a graph of time to peak in iN cells of HC and iN cells of BP patients. Figure 1C is a graph of peak amplitude in HC and BP patients. Figure 1D is a graph of slope in HC and BP patients. Figure 1E is a graph of baseline [Ca] in HC and BP patients.2+ This is a graph of ]i. Demographic information for HC and BP patients is shown in Table 1 below.
[0028] [Table 1]
[0029] Ca in nerve cells of BP patients 2+ The degree of kinetic delay is expected to correlate particularly strongly with the number of manic episodes among many clinical features, suggesting that this cellular-level deficiency may underlie the phase transition from depressive to manic states. This phase transition is central to the clinical features of BP, is a major cause of poor prognosis, and also contributes to treatment-resistant, rapidly alternating BP cases. Figure 2 is a graph showing the correlation between the time to peak and the number of manic episodes in BP patients. Representative clinical features used to correlate with the results in Figure 2 are shown in Table 2 below.
[0030] [Table 2]
[0031] At the molecular level, this cellular-level deficiency (Ca 2+ The kinetic delay is mediated by a decrease in supercomplex formation between L-type voltage-gated calcium channels (e.g., CaV1.2) and BK channels. Figure 3A shows the detection of in situ proximity ligation assay (PLA) signals detecting the colocalization of CaV1.2 and BK. PLA signals (red dots) probed with anti-CaV1.2 antibody and anti-BK channel antibody were detected in iPSC-neurons derived from HC and BP subjects. Figure 3B is a graph showing a significant decrease in CaV1.2-BK channel interaction in BP subjects. The data in this figure suggest that the underlying mechanism of calcium signaling abnormalities is due to attenuation of the protein-protein interaction between CaV1.2 and BK. Figures 3C and 3D show that the expression levels of CaV1.2 (L-type voltage-gated calcium channel) and BK 1.1 (BK channel) remain unchanged.
[0032] BK channel activators such as Uno and NS1619 have been found to be effective in ameliorating this cellular-level deficit in BP patient neurons. In particular, the BK channel activator Uno is effective in rescuing this cellular-level deficit not only in neurons derived from BP patients who respond to Li (responders), but also in neurons derived from BP patients who do not respond to Li (non-responders). In contrast, Li rescues this cellular-level deficit only in neurons derived from responders, and is not effective in neurons derived from non-responders. Figure 4A shows delayed Ca in BP neurons 2+ It is a bar graph showing that the kinetics (delay in time to peak) were rescued by the BK channel agonists Uno and NS1619. Figures 4B and 4C show Ca in BP neurons 2+ Individual data for kinetics (time to peak and peak amplitude) are shown.
[0033] Figure 4D shows that the BK channel agonist Uno delayed Ca in both neurons derived from Li responders and non-responders 2+ It is a bar graph showing that the kinetics (delay in time to peak) were rescued. In Li responders, both Uno and Li delayed Ca 2+ Kinetics were rescued. In Li non-responders, Uno delayed Ca 2+ Kinetics were rescued, but Li was not effective. While not wishing to be bound by any particular theory, this finding indicates the possibility that BK channel agonists can be effective therapeutic agents for Li non-responders.
[0034] This disclosure evaluates the mechanisms of bipolar disorder in human-derived neurons. While not wishing to be bound by any particular theory, it is thought that the primary mechanism of bipolar disorder in human-derived neurons, particularly mood swings, may lead to a major cellular phenotype of calcium signaling deficiency by providing a novel mechanism of attenuation of the protein-protein interaction between CaV1.2 and BK. In some embodiments, methods are provided for evaluating the mechanisms of bipolar disorder in human-derived neurons, the mechanism of which mood swings are the cause and which leads to calcium signaling deficiency by attenuation of the protein-protein interaction between CaV1.2 and BK.
[0035] Combining human cell biology data with clinical data analysis from the same bipolar disorder (BP) patient population, the biological mechanisms described herein clearly demonstrate the involvement of the phase transition from depressive to manic episodes in BP. However, no mouse model exists that centrally models this BP feature. Therefore, this disclosure provides a novel mouse model that addresses this feature by combining BK channel haploinsufficiency with mild stressors such as short-term sleep deprivation (SD). In some embodiments, genetically modified mice characterized by BK channel knockout (KO) are provided. Genetically modified mice can be used to evaluate the efficacy of therapeutic agents in the treatment of BP patients, including lithium-responsive and lithium-nonresponsive individuals, as described herein.
[0036] Using this model, behavioral changes were demonstrated in genetically modified mice conferring SD. No behavioral changes were observed when the same stressor, SD, was administered to wild-type mice (WT). Modulation of BK channels was sufficient only in excitatory neurons of the medial prefrontal cortex, indicating the neuronal / brain region involved in this phenotype. Furthermore, this pathological phenotype was observed to be completely rescued by administration of the BK channel activators Uno and NS1619.
[0037] In some embodiments, a method is provided for evaluating the efficacy of a composition in the treatment of bipolar disorder, which includes the steps of preparing a genetically modified non-human animal (e.g., a rodent such as a mouse or rat) exhibiting BK channel haploinsufficiency, administering the composition to the genetically modified non-human animal, exposing the genetically modified non-human animal to a mild stressor, and determining whether the genetically modified non-human animal exhibits behavioral change. In some embodiments, the mild stressor is a short period of sleep deprivation. In some embodiments, the step of subjecting the genetically modified non-human animal to a forced swim test before and after exposure to the mild stressor is further included. The presence or absence of behavioral change can be determined using the forced swim test. For example, the genetically modified non-human animal may exhibit different behavior in the forced swim test before and after exposure to the mild stressor, which indicates behavioral change. If behavioral change is prevented by administration of the composition, the composition may be effective in the treatment of bipolar disorder in some embodiments.
[0038] The mouse models disclosed herein can function as models of BP patients, and rescue of pathological phenotypes may suggest that therapeutic agents can be used to treat bipolar disorder. The mouse models and methods disclosed herein can be used in some embodiments for drug discovery and screening of BP therapeutic agents.
[0039] In some embodiments, a method is provided for treating a subject requiring treatment for bipolar disorder, comprising the step of administering a therapeutically effective dose of a BK channel agonist to the subject. In some embodiments, the BK channel agonist includes unoprostone, unoprostone derivatives, 1-(2'-hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone (also known as NS1619), benzimidazolones or their derivatives, or combinations thereof. Other BK channel activators and / or agonists known to those skilled in the art are also available in the methods of the present disclosure. For example, in some embodiments, the BK channel agonist is arachidonic acid, cytochrome P450 metabolites such as epoxygenase and lipoxygenase, docosahexaenoic acid, 17β-estradiol, tamoxifen, andrast, zonisamide, chlorzoxazone, cilostazol, human β-defensin 2, Cym04, N'-[3,5-bis(trifluoromethyl)phenyl]-N-[4-bromo-2-(2H-tetrazole-5-yl)-phenyl]thiourea (also known as NS11021), bis-(1,3-dibutylbarbiturate)tri This may include methine oxonol, 5-[(4-bromophenyl)methyl]-2-thiazoleamine (also known as NS19504), (3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-2H-indole-2-one (also known as BMS204352), 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinoline-2(1H)-one (also known as BMS-223131), analogues, and combinations thereof. Without being constrained by theory, compounds containing thiourea, tetrahydroquinoline, terpenes, and benzofreundole are considered to be other BK channel activators.
[0040] In some embodiments, the subject may be a lithium non-responder or a lithium responder. [Examples]
[0041] The following embodiments were carried out in accordance with the embodiments of the present disclosure.
[0042] BK het and WT mice were exposed to the mild stressor SD before the forced swim test (FST). Figure 5A is a schematic diagram of the FST with SD, and Figure 5B shows the total immobility time of WT and BK het KO mice with and without administration of the BK channel agonist Uno. WT mice showed no behavioral change or change due to the effect of Uno in the FST with the mild stressor. In contrast, BK heterozygous KO mice were less active (longer immobility time) before SD (week 0), more active after SD (week 4), and decreased again after a long washout from SD (week 12). This indicates a behavioral phase shift observed in BP. This phase shift in BK het KO mice was rescued by the BK channel agonist Uno. Figure 5C further shows that BK het KO (mPFC) mice also show a behavioral phase shift upon SD exposure. This suggests that BK plays a central role in the pathogenesis and phenotype of mPFC.
[0043] This disclosure is not limited to the specific systems, apparatus, and methods described herein, and these may be modified. The terms used herein are for illustrative purposes only and are not intended to limit the scope of any particular version or embodiment.
[0044] The above detailed description refers to the accompanying drawings, which constitute part of this specification. In the drawings, similar reference numerals generally indicate similar components, unless otherwise specified in context. The exemplary embodiments described in the detailed description, drawings, and claims are not intended to be limiting. Other embodiments may be used, and other modifications may be made, but not to the extent that they do not deviate from the spirit or scope of the subject matter disclosed herein. It will be readily apparent that each aspect of this disclosure, as generally described herein and shown in the figures, can be arranged, substituted, combined, separated, and designed in a variety of different configurations, all of which are expressly encompassed herein.
[0045] This disclosure is not limited to the specific embodiments described in this application, which are intended as examples of various aspects. It will be apparent to those skilled in the art that many modifications and variations are possible without deviating from its spirit and scope. Functionally equivalent methods and apparatus within the scope of this disclosure will be apparent to those skilled in the art from the foregoing description, in addition to those enumerated herein. Such modifications and variations are intended to be within the scope of the appended claims. This disclosure should be limited only by the language of the appended claims and the entire scope of their equivalents. It should be understood that this disclosure is not limited to specific methods, reagents, compounds, compositions, or biological systems, which are, of course, modifiable. It should also be understood that the terminology used herein is for the purpose of describing specific embodiments and is not intended to be limiting.
[0046] In this specification, with regard to the use of virtually all plural and / or singular terms, those skilled in the art can convert from plural to singular and / or singular to plural depending on the context and / or use. For clarity, various singular / plural combinations may be explicitly described herein.
[0047] Those skilled in the art will generally understand that the terms used herein, particularly in the appended claims (e.g., the body of the claims), are generally intended to be "open" terms (for example, the term "including" is interpreted as "including but not limited to," the term "having" is interpreted as "at least having," and the term "includes" is interpreted as "including but not limited to"). On the other hand, when various compositions, methods, and apparatus are described in terms of "comprising" various components or steps (interpreted as "including but not limited to"), these compositions, methods, and apparatus may also "consist essentially of" or "consist of" various components and steps, and such terms should be interpreted as essentially defining a closed group of components. Furthermore, those skilled in the art will understand that if a particular number of claims introduced is intended, that intention is explicitly stated in the claim, and if no such statement is made, no such intention exists.
[0048] For example, to aid understanding, the following attached claims may contain the phrases "at least one" or "one or more" as introductory phrases in the claims. However, the use of such phrases should not be interpreted as meaning that the indefinite article "a" or "an" in the claim introduction limits the claim to embodiments containing "only one," even if the same claim contains introductory phrases such as "one or more" or "at least one" and the indefinite article "a" or "an" (for example, "a" and / or "an" should be interpreted as "at least one" or "one or more"). The same applies to definite articles used in claim introductions.
[0049] In addition, even if a specific number of claims is explicitly stated, a person skilled in the art will recognize that such a statement should be interpreted as meaning at least the stated number (for example, if only "two statements" is stated, at least two, i.e., two or more statements). Also, when expressions such as "at least one of A, B, and C" are used, such a configuration is intended in the sense generally understood by a person skilled in the art (for example, "a system having at least one of A, B, and C" includes, but is not limited to, A alone, B alone, C alone, A and B together, A and C together, B and C together, a system having A, B, and C all of the above). Similarly, when expressions such as "at least one of A, B, or C" are used, such a configuration is intended in the sense generally understood by a person skilled in the art (for example, "a system having at least one of A, B, or C" includes, but is not limited to, A alone, B alone, C alone, A and B together, A and C together, B and C together, a system having A, B, and C all of the above). Furthermore, a person skilled in the art should understand that any separate words and / or expressions in a description, claim, or drawing that present two or more options are intended to include either one, either one or both, or both. For example, the expression "A or B" is understood to include the possibilities of "A" or "B" or "A and B".
[0050] Furthermore, if any feature or aspect of the disclosure is described from the perspective of the Markush Group, a person skilled in the art will recognize that the disclosure is also described from the perspective of an individual member or a subgroup of a member of the Markush Group.
[0051] Those skilled in the art will understand that, for any purpose, for example, in terms of disclosure requirements, all scopes disclosed herein encompass all possible subranges and their combinations. It is readily apparent that any scope described is divisible into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each scope discussed herein is readily divisible into lower thirds, middle thirds, upper thirds, etc. Furthermore, those skilled in the art will understand that expressions such as “maximum” and “at least” include the stated numerical values and refer to scopes divisible into subranges as described above. Moreover, those skilled in the art will understand that a scope includes each individual component. Therefore, for example, the group having compounds 1 to 3 refers to the group having compounds 1, 2, or 3. Similarly, the group having compounds 1 to 5 refers to the group having compounds 1, 2, 3, 4, or 5.
[0052] The various features and functions disclosed above, or their alternatives, may be combined with many other different systems or applications. Various alternatives, modifications, variations, or improvements not foreseen or anticipated herein may be made later by those skilled in the art, but these are also intended to be incorporated into the disclosed embodiments.
[0053] (Big potassium channel knockout mice as a behavioral change model for bipolar disorder research)
[0054] Bipolar disorder is a major mental disorder characterized by mood swings between depressive and manic episodes. Its mechanistic understanding remains challenging due to the complex genetic and environmental factors contributing to its etiology and pathogenesis. Furthermore, creating animal models that can mimic the characteristic “switch” process is difficult. Based on our unpublished prior research, we identified calcium and voltage-gated big potassium (BK) channels as key factors in cellular dysfunction in neurons derived from bipolar disorder patients. In this study, we mimicked the “switch” process by combining BK channel gene knockout (KO) with the environmental stressor of sleep deprivation. As a result, BK KO heterozygous (het) mice showed higher immobility times at baseline in the forced swim test (FST). Exposure of these mice to 4 hours of sleep deprivation resulted in a “switch” towards reduced immobility. This behavior reversed after several weeks of rest. The effects of sleep deprivation lasted for at least several days, and even after 5 days of sleep deprivation, the mice still showed reduced immobility. Of particular note is that the "conversion" behavior was rescued by injection of a BK channel agonist. This study characterized an important mouse model system based on the mechanisms of bipolar disorder that exhibit "conversion" behavior. BK channels may be important targets for application in the treatment of bipolar disorder.
[0055] (method)
[0056] As described in the abstract section, our preliminary studies using a human-derived neural model system revealed the importance of BK channels, particularly their interaction with voltage-gated calcium channels, in the development of bipolar disorder (data not shown herein). Building on this foundational research, this study further demonstrated that loss of BK channel function, combined with environmental stressors, can trigger a "behavioral phase shift" in a mouse model.
[0057] CaMKIIα-specific KCNMA1 (BK channel) knockout and brain region BK knockout were subjected to repeated fast-paced sleep training (FST) at intervals as shown in the figure. The numbers on the line indicate the assay timing (weeks). Red arrow: timing of sleep deprivation (SD). Black arrow: timing of FST performed for the experiment. The FST was performed for a total of 6 minutes, and motion and immobility scoring of the video was performed for the entire duration.
[0058] mPFC-specific CaMKIIα-driven BK channel knockout mice were generated by injecting an AAV (Addgene, 105551-AAV9) expressing GFP-CRE under the CaMKIIα promoter. Injection site: Coordinates from Bregma; +1.94 mm AP, ±0.5 mm ML, -1.5 mm DV.
[0059] SD was performed over a period of 4 hours, starting from Zeitgeber time 0 (ZT0). Mice were gently awakened by gently shaking their enclosure. Food and water gel were available for consumption at any time.
[0060] Unoprostone isopropyl ester (1 μM) or physiological saline was administered intraperitoneally, and FST was performed on mice 20 minutes later.
[0061] (result)
[0062] Immunofluorescence validation of BK KO Het mice. 40x magnification image of the layer III mPFC region (Figure 6).
[0063] Genetically CaMKIIα-specific BK Het KO mice exhibit a behavioral phase shift upon exposure to sleep deprivation (SD). Wild-type (WT) mice do not show a significant difference (Figure 7A). This behavioral phase shift persists in BK Het KO mice even 5 days after SD exposure. After several weeks of rest, the phenotype returns to baseline (Figure 7B).
[0064] Repeated exposure of BK Het KO mice to stable disease (SD) after a normal rest period resulted in repeated behavioral phase transitions (Figure 5B). In genetically CaMKIIa-BK Het KO mice, behavioral phase transitions were restored by the BK channel agonist Uno. Baseline mobility in FST of Het mice reached the level of WT mice, and no behavioral phase transitions were observed after administration of Uno following SD (Figure 5B).
[0065] Conditionally mPFC-specific CaMKIIα-specific BK KO Het mice (pink) exhibit behavioral phase shifts upon SD exposure, similar to those observed in whole-brain CaMKIIα-specific BK KO mice (Figure 7A). Conditionally mPFC-specific CaMKIIα-specific BK KO Het mice demonstrate a dose-response effect on BK channels, and the phenotype of Homo KO mice was found to be more pronounced in response to behavioral phase shifts than that of Het mice (Figure 9).
[0066] CaMKIIα-driven BK channel heterozygous knockout (Het KO) mice exhibit higher immobility times during fasting time (FST) at baseline. This behavior "switches" to shorter immobility times when the mice are exposed to acute sleep deprivation (SD). This behavior returns to baseline levels of higher immobility times after several weeks of rest. This "behavioral phase switch" occurs repeatedly with each exposure to SD. The SD effect is long-lasting, and the "behavioral phase switch" is observed at least 5 days after SD. BK channel agonists (Uno) can rescue the "behavioral phase switch" in BK Het KO mice. mPFC-specific CaMKIIα-BK KO mice also exhibit the "behavioral phase switch," with homozygous knockouts (Homo KO) showing a stronger phenotype than heterozygous mice. Currently, CaMKIIα-BK channel agonists can be obtained from the mPFC region of BK Het KO and WT mice using in vivo fiber photometry. 2+ Transient recording is being performed.
[0067] Figure 6 shows immunostaining of CaV1.2 and BK channels in nerve cells, illustrating representative immunofluorescence validation of BK KO Het mice. The images are 40x magnification images from layer III of the mPFC region.
[0068] Figures 7A-7B demonstrate that genetic CaMKIIα-specific BK Het knockout induces a long-term behavioral phase switch in mice upon SD exposure. Figure 7A is a graph showing the total immobility time on day 1 of SD, comparing genetic CaMKIIα-specific BK Het knockout mice (indicated by arrows) with the WT. Figure 7B is a graph showing the total immobility time 5 weeks after SD exposure, comparing genetic CaMKIIα-specific BK Het knockout mice (indicated by arrows) with the WT. BK HETs exhibit an SD-induced behavioral phase switch (a shift from a more immobile to a less immobile state compared to the WT). SD does not affect the WT. Week 0: 5 is 1 week after SD (and therefore 5 weeks after baseline FST), and the SD-induced switch state is still maintained. 12 is 8 weeks after SD (and therefore 12 weeks after baseline FST), and the behavior of BK HETs at FST returns to baseline (default state).
[0069] Figure 8 shows that repeated exposure of BK Het KO mice to SD after a normal rest period results in repeated behavioral phase switching.
[0070] Figure 9 shows that BK KO Het mice exhibit a dose-response effect on BK channels. Specifically, the behavioral phase switch in homozygous KO mice was more pronounced compared to Het mice.
[0071] (Ca 2+ (And voltage-gated big potassium (BK) channels will be targeted as templates for a novel bipolar disorder (phase-switching) mouse model.)
[0072] (Bipolar disorder and phase switching.)
[0073] Bipolar disorder is a serious mental illness characterized by mood swings (phase switches) between depressive and manic episodes. These switches are known to be frequently triggered by stress, such as sleep disturbances. However, intracellular calcium (Ca) 2+ Aside from recent advances in psychogenetics suggesting the involvement of signal transduction, the biological and molecular mechanisms of bipolar disorder remain unclear. As a result, patients with bipolar disorder lack adequate treatment options, leading to long-term disability and a high suicide rate (15-20% of patients). The establishment of novel animal models that express phase switching based on these mechanisms is urgently needed.
[0074] (Ca as a template for a novel bipolar disorder (phase-switched) mouse model) 2+ And the rationale for targeting voltage-gated big potassium (BK) channels.
[0075] Our laboratory has focused on discovering cellular-level defects associated with mental illnesses such as bipolar disorder. We recruit patients ourselves, characterize them from a multidimensional perspective, and explore specific clinical features associated with unique cellular defects. Through these studies, we have found that induced neurons (iN cells) and induced pluripotent stem cell-derived neurons (iPSC-neurons) from bipolar disorder patients have Ca compared to controls. 2+ Specific deficiencies in dynamics (Ca after depolarization stimulation) 2+ We identified a time delay to the peak (see Figure 4A). These neurons were CaMKIIα-positive and glutamatergic (Figure 10). Most importantly, the degree of deficiency in patient neurons was specifically and significantly correlated with the number of manic episodes in patients, considering 20 clinical features. This positive conclusion was maintained after considering multiple confounding factors such as disease duration and correcting for multiple tests (Figure 2). These data show intracellular Ca in CaMKIIα-positive glutamatergic neurons. 2+ This suggests that a loss in signal transduction can be the basis for phase switching.
[0076] Slower Ca 2+To elucidate the mechanism of time to peak, we investigated several compounds targeting various types of calcium-driven calcium channels and other ion channels, including L-type voltage-gated calcium channels (VGCCs) and calcium-activated big potassium (BK) channels. Among these compounds, unoprostone (Uno), a BK channel agonist, was the most effective. 2+ The signaling deficiency was almost completely normalized (Figure 4A). To confirm that BK channel regulation is specifically effective, another BK channel agonist, NS1619, was also tested, and a significant rescue effect against the deficiency was observed (Figure 4A). 2+ The agonist NS309, which targets activated intermediate potassium (IK) and small potassium (SK) channels, was ineffective, supporting the specificity of BK channels. Lithium (Li) is used as a first-line treatment for bipolar disorder, but many patients do not respond to this drug. This suggests that Li may not improve all aspects of the disease's pathophysiology. At least under the conditions we examined, Li was ineffective (Figure 4D). We can optimistically hypothesize that BK channel agonists may be able to rescue some of the disease mechanisms that Li cannot rescue.
[0077] Under physiological conditions, stimulation-induced activation of VGCC activates BK channels, Ca 2+ This results in precise control of inflow. These channels (VGCC and BK channels) have been reported to interact physically and functionally to form a supercomplex. Therefore, loss of function of this complex leads to Ca 2+ This leads to a loss of signal transduction. Therefore, we investigated whether channel-protein interactions are impaired in neurons derived from bipolar disorder patients. Using proximity ligation assay (PLA), we obtained promising preliminary results indicating attenuation of channel-protein interactions in neurons from bipolar disorder patients (Figure 3A).
[0078] In summary, the attenuation of protein-protein interactions (BK and VGCC) is associated with Ca in glutamatergic neurons of patients with bipolar disorder. 2+ We hypothesized that this underlies a signaling deficiency, which specifically correlates with the number of manic episodes and likely reflects mood disturbance. Several groups have attempted to establish mouse models that express bipolar disorder, particularly its mood disturbance features. Our data linking our human cell model with clinical information (Figure 10) provides strong evidence for exploring mice that mimic attenuation of the interaction between VGCC and BK channels, aiming to establish a novel model of bipolar disorder (at least a phase-switch model). As a first step in this approach, we decided to validate a BK channel heterozygote knockout model (haploinsufficiency) that can mimic attenuation of channel interaction. More specifically, the model used in this proposal is a potassium-calcium-activated channel subfamily M-alpha-1 (Kcnma1) heterozygote knockout model (see Methodology). In this proposal, we refer to this model as BK HET.
[0079] Figure 10: Role of BK channels in neurons of patients with bipolar disorder. Original subjects: 24 patients and 25 healthy controls. iN cells and iPSC-neurons express CaMKIIα and are glutamatergic / excitatory.
[0080] (Innovation)
[0081] (1) This study aims to establish a novel bipolar disorder model that can also represent behavioral phase transitions. The uniqueness of this study lies in establishing the rationale for using BK HET as a template based on preliminary data linking human cell models with clinical information (see Figures 4A and 42 above).
[0082] (2) Clinically, mood phase shifts often occur in association with stress events. As shown in the preliminary data below (Figures 7B and 11A), a mild stressor [sleep deprivation (SD)] that does not affect wild-type (WT) mice but affects only BK HET mice is effectively utilized.
[0083] (3) Behavioral abnormalities (phase transition) in BK HET are improved by the BK channel agonist Uno. The same pharmacological agent improves Ca in glutamatergic neurons derived from bipolar disorder patients. 2+ It is also effective in vitro in normalizing signal transduction deficiencies (Figure 4A). Therefore, BK channel agonists can be an effective tool for linking human cell models and animal models at the mechanistic level.
[0084] (4) Furthermore, the BK channelagonist Uno has been used as a treatment for glaucoma. Repositioning is generally considered an efficient strategy in drug discovery. Therefore, BK channelagonists may be repositioned for the treatment of bipolar disorder. Thus, BK HET could be used as a model for bipolar disorder.
[0085] (approach)
[0086] (Part 1: Preliminary Research)
[0087] The transition from a high state of immobility to a low state of immobility in the Forced Swimming Test (FST) is observed in the Backstroke Hemostatic Test (BK HET) compared to the Weighted Throw (WT).
[0088] We first explored behavioral phase shifts that may be induced by mild stressors in BK HET but not in WT. Clinically, sleep disturbances can be such stressors. Therefore, we selected SD as a potential stressor. As a behavioral assay, we chose FST. While FST is in principle a measure of stress coping (adaptive) behavior, it has been primarily used in drug discovery to test the efficacy of antidepressants. Furthermore, FST behavior is known to be mediated by excitatory neurons in layer 5 of the medial prefrontal cortex (mPFC), which are suggested to be involved in the pathophysiology of bipolar disorder.
[0089] We observed that BK HET showed significantly higher immobility times in FST compared to WT (Figure 5A, Figure 7B, Week 0). Four weeks after assessing baseline behavior, we administered acute SD for 4 hours to both the BK HET and WT groups. The choice of "4 weeks" was made to avoid "learned immobility" caused by repeating FST at insufficient intervals. This mild stressor did not alter WT behavior when monitored immediately after SD (Figure 5A and Figure 7B, Week 4). In contrast, a significant change in FST behavior was observed in BK HET. As mentioned above, immobility times were longer than in WT at baseline, but immediately after SD, BK HET had shorter immobility times than WT (Figure 5A, Figure 7B, Week 4). This change appears to be a "phase reversal" in comparison to WT in BK HET.
[0090] This shift is unlikely to be merely an acute reaction, as the reduced immobility time was maintained for at least one week (5 weeks in Figures 5A and 7B) that we examined. Interestingly, this stress-induced state in BK HET disappeared, and the patient returned to their original state (baseline level) 8 weeks after the shift induced by SD. In fact, without additional intervention after SD, BK HET again showed significantly higher immobility time compared to WT (12 weeks in Figures 5A and 7B).
[0091] Rescue of BK HET phase conversion by BK channel agonist Uno: At least in neurons derived from bipolar disorder patients, Ca25 is correlated with the number of manic episodes. 2+Signaling deficiencies (and therefore potentially related to mood swings) were rescued in vitro by BK channel agonists (both Uno and NS1619). Therefore, we investigated whether BK channel agonists could rescue BK HET phase transition in vivo. At each stage (baseline, SD, default), 1 μM Uno or saline was administered intraperitoneally (IP) 20 minutes prior to behavioral testing. This dose was chosen because preliminary data from an independent study suggested that a 1 μM IP administration resulted in a brain concentration of approximately 10 nM Uno 1 hour later. Interestingly, this drug not only rescued the high immobility phenotype at the baseline and default stages (weeks 0 and 12, respectively: see Figure 5A), but also rescued the transition at SD. No statistically significant effect was observed with these administrations in WT mice.
[0092] mPFC-specific BK HET: To date, we have obtained promising preliminary results using a BK HET model (BK channel haploinsufficiency in CaMKIIα-positive cells throughout the brain) (Figure 7B). Since FST behavior is known to be mediated by excitatory neurons in layer 5 of the mPFC, we further investigated mPFC-specific BK HET. We generated medial prefrontal cortex (mPFC)-specific BK HET by stereotactic intracerebral injection of AAV (Addgene, 105551-AAV9) expressing GFP-Cre driven by the CamKII promoter into progeny mice of BK(fl / +)x(fl / +). The control group consisted of wild-type mice that underwent similar viral injection. We observed consistent phase transitions induced by SD in mPFC-specific BK HET (Figures 11A-11B), demonstrating that BK dysfunction in mPFC CaMKII-positive excitatory neurons is sufficient to explain the phase transitions.
[0093] (Calcium abnormalities and the role of potassium channels in BP)
[0094] Bipolar disorder (BP) is a serious mental illness, but its disease mechanisms are still not fully understood. BP is a chronic disease, and due to inadequate treatment options, it leads to long-term disability and a high suicide rate (15-20% of patients). The etiology of this disorder may be complex and multifactorial, involving genetic predisposition and environmental factors. 8 Understanding the major pathophysiological mechanisms by which multifactorial etiologies converge is needed. Several suggestive pieces of evidence indicate the involvement of excitatory neuronal circuits in the pathophysiology of BP.
[0095] Calcium (Ca 2+ Signal transduction deficiencies have also been suggested in BP, and this is now scientifically supported by compelling data in psychogenetics (emphasis on CACNA1C and CACNB3 in association with BP). These genes encode voltage-gated calcium channels (VGCCs) (e.g., CaV1.2 protein) and their regulatory subunits. Furthermore, changes in spontaneous neuronal activity associated with BP have been reported using induced pluripotent stem cell (iPSC)-derived neurons. However, in response to a crucial stimulus for neuronal activation, depolarization signaling, Ca in disease states is not considered. 2+ Our understanding of how signal transduction changes remains limited. Overall, Ca is considered a potential cellular abnormality associated with BP. 2+ Studying signal transduction is a rational approach to elucidating the pathophysiology of BP. Under physiological conditions, stimulus-induced VGCC activation leads to downstream activation of calcium and voltage-gated big potassium (BK) channels, which in turn feeds back to VGCC via Ca 2+ They control the inflow. These channels (CaV1.2-BK channels) have been reported to function as a supercomplex at close range of a few nanometers.
[0096] (A human neuronal cell model system for studying BP)
[0097] iPSC-derived neurons are frequently used to investigate neuronal abnormalities. A drawback of this experimental strategy is the difficulty in scaling up sample size. While it is possible to assume common deficiencies in BP patients, it must be recognized that BP is a clinical syndrome and potentially heterogeneous at the biological level. Therefore, it may be necessary to validate a reasonable number of patients compared to healthy controls (HC) before focusing on a specific working hypothesis. In this sense, the use of directly converted or induced neurons (iN cells) provides an excellent model, allowing for the generation of cells from a fairly large number of subjects for quantitative comparison. These cells express mature neuronal cell markers (such as MAP2 and αCaMKII) and exhibit electrical activity that mimics several features of human neuronal cell-type cells. By analyzing the cellular phenotype in iN cells along with clinical features, it may be possible to stratify subjects based on clinically relevant cellular phenotypes. Accordingly, iPSC lines can be generated from selected subjects for further study. Thus, these two human neuronal cell model systems offer an opportunity to complementarily study clinically relevant phenotypes and pathophysiological mechanisms.
[0098] (Innovation)
[0099] (1) This study will complementarily utilize two human neuronal cell model systems (iN cells and iPSC-derived neurons) to elucidate the clinically relevant pathophysiology of BP.
[0100] (2) This study investigated the Ca in the pathophysiology of BP. 2+ We propose a novel molecular mechanism (impairment of CaV1.2-BK channel interaction) based on signal transduction deficiencies.
[0101] (3) This study identifies BK channels as potential therapeutic targets for BP through cellular phenotypes associated with BP.
[0102] (approach)
[0103] (Part 1: Preliminary Research)
[0104] (Ca in iN cells related to BP) 2+ (Delay in dynamics)
[0105] We have a published protocol for generating excitable and αCaMKII-positive iN cells 41-42. We have analyzed the basal intracellular Ca in iN cells generated from 25 bipolar disorder (BP) patients and 25 healthy controls (HC) (see "Subjects"). 2+ and depolarization-inducible Ca 2+ The dynamics were investigated. Basal intracellular Ca between BP patients and HC 2+ Although no significant difference was observed, BP patients showed depolarization-induced Ca compared to HC. 2+ A delayed phenotype (longer time to peak) was observed. Detailed clinical information was obtained for each subject who provided cells through diagnostic interviews (DIGS) for genetic studies. Among many clinical factors, only one factor (number of manic episodes) correlated with this cellular phenotype (time to peak). This conclusion is based on partial correlation analysis and Bonferroni-corrected analysis for multiple testing, controlling for potential confounding factors (including drug treatment).
[0106] Delayed Ca in BP-related iN cells 2+ Main contribution of BK channels in dynamics
[0107] We have various membrane-bound and intracellular Ca2+ 2+ A series of pharmacological evaluations were performed using channel activators and / or inhibitors. Delayed Ca 2+ The kinetics were further delayed by VGCC inhibitors, such as verapamil (for L-type CaV1.2) and ω-agatoxin TK (for P / Q-type CaV2.1), but not altered by fwentoxin XVI (N-type CaV2.2 VGCC inhibitor) or SNX-482 (R-type CaV2.3 VGCC inhibitor) (Figure 7B). Other membrane-bound or intracellular Ca 2+Channel modulators, such as dantrolene (ryanodine receptor inhibitor), thapsigargin (SERCA inhibitor), 2-aminoethoxydiphenylborane, and 2-APB (TRP channel and IP3 receptor modulators, respectively), did not significantly affect the time to peak (Figure 7B). These data suggest that delayed Ca related to BP is not significantly affected. 2+ This suggests that L-type VGCC may be involved in the dynamics. In fact, the L-type VGCC activator FPL64176 partially rescued the disease phenotype.
[0108] As mentioned above, potassium channels, especially BK channels, are Ca 2+ Because potassium channels play a crucial role in signal transduction, we also investigated drugs targeting potassium channels. Interestingly, when using the BK channel agonist unoprostone (Uno), a more pronounced rescue was observed, and the BP phenotype (delayed Ca) was affected. 2+ Dynamics and the time to peak were completely normalized to HC levels (Figure 11). Also, Ca 2+ The effect of NS309, a positive modulator of activated small and medium potassium channels, was also investigated, but Ca 2+ No improvement was observed in the dynamics (data not shown), which suggests the contribution of a specific potassium channel (BK channel).
[0109] Figure 11: L-type voltage-gated calcium channels are delayed Ca 2+ It contributes to the dynamics (Figure 11A), but membrane-bound or intracellular Ca 2+ Channel modulators do not contribute (Figure 11B).
[0110] Figure 12: Delayed Ca in BP iN cells 2+ The dynamics were rescued by the BK channel agonist Uno.
[0111] (Decreased potassium current in BP iN cells)
[0112] Given the focus on BK channels in pharmacological studies, we then compared potassium currents in iN cells derived from three HC patients and three BP patients using whole-cell patch-clamp recording (10–15 cells recorded per subject). In voltage steps from 0–60 mV, BP cells showed significantly lower peak amplitudes compared to HC cells (no difference was observed in low-voltage steps). This indicates that BP cells exhibit reduced potassium current even after accounting for cell volume. Figure 13 shows the difference in outward current density at the 60 mV voltage step.
[0113] Figure 13: (A,B) Whole-cell patch-clamp current recordings of αCaMKII iN cells; Figure 13C: Representative data: BP iN cells have low outward current density (peak amplitude quantified after leak subtraction and normalized by cell volume).
[0114] (BP iPSC-delayed Ca in nerve cells) 2+ (Rescue by dynamic and BK channel agonists)
[0115] To further characterize the BP-related cell deficiency identified in iN cells, we investigated iPSC-derived neurons (see above). Approximately 80% of these cells were CaMKII-positive and approximately 12% were GAD67-positive neurons, with no significant difference observed between the BP and HC groups (data not shown). These cells also expressed cerebral cortical neuronal markers, with no differences between the BP and HC groups (Figure 14). Similar to iN cells, αCaMKII-positive excitatory iPSC neurons also expressed Ca 2+ Dynamic delays were observed (Figure 4B). These disruptions were rescued by the BK channel agonist Uno (Figure 4B).
[0116] (Decreased spike frequency in BP neuronal networks and rescue by Uno: Data from multi-electrode arrays (MEA))
[0117] We investigated network-level activity (multi-electrode array, MEA) of excitatory iPSC-derived neurons while GABAergic neurons were blocked with bicuculin (10 μM). BP-excitatory iPSC neurons showed a reduced frequency of depolarization-induced spikes at the network level, and the BK channel agonist Uno was able to rescue this phenotype (Figure 15).
[0118] Figure 14: No significant difference was observed between control and BP iPSC neuronal cell cultures regarding cerebral cortical marker staining.
[0119] Figure 15: Reduction in spike frequency at baseline levels in MEA recordings (left graph) and rescue by the BK channel agonist Uno (right graph). The two controls are shown as a combined bar, and each BP line is shown individually.
[0120] (CaV1.2-BK channel protein interaction in iPSC neurons)
[0121] In at least one subject, CaV1.2-BK channel protein expression and interaction were confirmed by Western blotting and co-immunoprecipitation (co-IP) (Figure 16). Therefore, in situ proximity ligation assay (PLA) was used to investigate whether protein-protein interactions were altered in BP. Significant differences were observed between the two HC and five BP patients examined. At least in preliminary studies, the signal intensity of CaV1.2-BK channel interactions in the cell body and protrusions (10 μm from the cell body) of BP cells was significantly lower compared to HC cells.
[0122] Figure 16: Co-IP of CaV1.2-BK channels in a network of 3-month-old neurons derived from a single HC. An anti-CaV1.2 primary antibody was used to immobilize the complex on agarose, followed by Western blotting with an anti-BK channel antibody.
[0123] (Modeling of medial prefrontal cortex (mPFC)-related behaviors / mood changes in mice)
[0124] Our initial submission demonstrated abnormalities in baseline adaptive behavior [forced swimming test (FST)] in BK heterozygous knockout mice (BKhet). Upon application of a mild stressor (mild sleep deprivation), the abnormalities in BKhet reversed compared to healthy wild-type (WT) mice. Therefore, we proposed these phenotypes as a potential model for mood changes observed in patients with bipolar disorder.
[0125] However, this argument remains largely unclear. To strengthen the argument, we also examined BKhet's baseline behavior using other paradigms, such as the sucrose splash test (SST) and the open field test (OFT).
[0126] While fast-paced grooming (FST) is known as a behavioral paradigm involving the mPFC, open-ended grooming (OFT) is known as a behavioral paradigm that does not involve the mPFC. Considering the involvement of the mPFC in the pathophysiology of bipolar disorder, we investigated whether the mPFC is involved in behavior during social grooming (SST). To address this challenge, we induced lesions in the mPFC by local toxin injection and evaluated the behavioral outcomes. As shown in Figure 17, mice with mPFC lesions exhibited a deficiency in grooming frequency during SST, suggesting that the mPFC is involved in this behavioral paradigm.
[0127] Figure 17: Lesions in the medial prefrontal cortex (mPFC) caused changes in grooming frequency in the sucrose splash test.
[0128] Next, we examined behavioral abnormalities in BKhet compared to WT in baseline SST and OFT (Figure 18). Consistent with previous reports, we confirmed that BKhet exhibited behavioral abnormalities in FST compared to WT. Similarly, BKhet showed significant abnormalities in SST compared to WT. In contrast, no abnormalities were observed in BKhet in OFT.
[0129] Figure 18: BK knockout mice showed significant changes in the forced swimming test (Figure 18A) and the sucrose splash test (Figure 18B), but no changes in the open field test (Figure 18C).
[0130] Following the experimental flow shown in Figure 5A, we investigated whether a mild stressor (mild sleep deprivation) could affect the behavior of BK heterozygotes and wild-type mice over time. We previously showed that behavioral abnormalities observed in the forced swim test (FST) in BK heterozygotes shifted to significant abnormalities on the opposite side in response to mild stressors, but such changes were not observed in wild-type mice. Furthermore, the shifted abnormalities disappeared, and it was confirmed that they returned to their original state 8 weeks after the stressor. We improved our data analysis in the FST, and the newly analyzed data are shown in Figure 19A. These phenotypes (rapid shifts in abnormalities due to stressors and return to the original abnormalities several weeks after the rapid event) were also observed in the stress test (SST) (Figure 19B). Therefore, we observed behavioral shifts in these mPFC-related behaviors. In contrast, no differences were observed between BK heterozygotes and wild-type mice in the OFT, an mPFC-unrelated behavior. Both mice exhibited similar levels of irreversible low activity after mild stressors, and no BK-specific abnormalities or behavioral changes compared to wild mice were observed (Figure 19C).
[0131] Figure 19: Specificity of behavioral change in BK knockout het mice. WT mice did not show behavioral change in response to mild stressors in the forced swimming test, namely short-term sleep deprivation (SD). In contrast, BK KO mice showed low activity (long periods of immobility) before SD (week 0), became highly active after SD (week 4), and returned to a low-activity state after a long washout period from SD (week 12) (Figure 19A). BK KO mice showed low activity (low grooming frequency) before SD, became highly active after SD, and returned to a low-activity state after a long washout period from SD, but WT mice did not show behavioral change in the sucrose splash test (Figure 19B). No differences were observed between BK and WT mice in the open field test (Figure 19C).
[0132] Finally, as shown in Figure 19A, the data examining the effect of unoprostone (Uno) on FST were reanalyzed. The new analysis yielded the same conclusions as the original patent application (Figure 20). In short, Uno improved baseline behavioral abnormalities. No acute phenotypes were observed under Uno administration.
[0133] Figure 20: Behavioral changes in the forced swim test were rescued by Uno, which also improved the delay in time to peak in BP cells.
[0134] In summary, this study improved the concept of the animal model. The claim is that mPFC-related behavioral abnormalities are observed in BK haploinsufficiency (loss-of-function model). Mild sleep deprivation (mild stressor) causes this abnormality to abruptly change to a significant abnormality on the opposite side. The abruptly changed abnormality disappears, and in the BK model, the abnormality returns to the baseline level.
[0135] These changes in mice are reminiscent of the pathophysiology and clinical phenotype of bipolar disorder, such as mPFC abnormalities observed in brain imaging, and mood shifts from depressive to manic states, often induced by stressors including sleep deprivation, followed by a return to depressive states.
[0136] ((II) Intervention)
[0137] This application is based on a novel mechanism in patients with bipolar disorder, in which attenuation of the protein-protein interaction between VDCC / CaV1.2 and BK channels leads to a decrease in BK-dependent potassium outward current (reflecting attenuation of BK function) and results in a "delay in time to calcium peak after neuronal activation" (Figure 20). The clinical and translational significance of this "delay in time to calcium peak after neuronal activation" in bipolar disorder is supported by our rigorous study examining the potential association between this cellular phenotype and clinical features. Of 20 independent clinical features, after collecting multiple comparisons, only one specific feature (number of manic episodes) showed a strong correlation with this cellular phenotype (already included in the original application).
[0138] Figure 20: Novel underlying mechanism of BP: Attenuation of protein-protein interaction between VDCC / CaV1.2 and BK channels. EM: Estramustin, CaVC-pep, CaV1.2 C-terminal peptide.
[0139] (Pharmacological intervention)
[0140] To enhance the proof-of-concept (POC) and clinical applicability of this discovery, we searched for further compounds that could improve the "delay in time to calcium peak after neuronal activation" associated with bipolar disorder at the neuronal level. As shown in Figure 21A, we conducted a systematic bioinformatics analysis starting with the search for BK channel interactors and narrowed it down to two candidate compounds (estramustine and fluticasone propionate). Accordingly, we observed that applying estramustine to neuronal cell culture significantly improved the "delay in time to calcium peak after neuronal activation" associated with bipolar disorder (Figure 21B). Estramustine is known to interfere with cytoskeleton and protein-protein interactions. Therefore, it is likely that it affects the protein-protein interaction between VDCC / CaV1.2 and BK channels by interacting with BK channels. Thus, we propose that a range of small molecule compounds that can modulate the protein-protein interaction between VDCC / CaV1.2 and BK channels may also be potential therapeutic candidates for mood changes in bipolar disorder.
[0141] Figure 21: BP-related Ca 2+ Pharmacological intervention for signal transduction deficiencies. Schematic diagram of candidate selection (Figure 21A). Estramustine-induced delayed Ca in BP neurons. 2+ Rescue time to peak. Number of subjects: HC=3, BP=2, BP+EM=2. Number of cells: HC=37, BP=50, BP+EM=55 (Figure 21B).
[0142] (molecular intervention)
[0143] To enhance the proof-of-concept (POC) of this discovery, and to demonstrate how the protein-protein interaction between VDCC / CaV1.2 and BK channels affects the "time to the calcium peak after neuronal activation," we directly interfered with the protein-protein interaction using molecular tools. When CaV1.2 C-terminal peptide (Figure 22A) was expressed in neurons, interference with the protein-protein interaction was observed, mimicking, at least partially, the attenuated protein-protein interaction seen in neurons derived from bipolar disorder patients (Figure 22B). Under these conditions, a "delay in the time to the calcium peak after neuronal activation" was also observed (Figure 22C). These data clearly demonstrate that attenuation of the protein-protein interaction between VDCC / CaV1.2 and BK channels results in a "delay in the time to the calcium peak after neuronal activation," which is observed in neurons derived from bipolar disorder patients, thus providing a new POC for this discovery.
[0144] Figure 22: Molecular manipulation to induce the BP phenotype in HC neurons. Molecular structure of CaV1.2 (Figure 22A). The CaV1.2 C-terminal peptide (CaVC-pep) significantly reduced BK-CaV1.2 channel interaction as assessed by PLA. In this analysis, assuming that PLA data were unaffected by methodological changes, some missing data were estimated by integrating two methods (Figure 22B). CaVC-pep induced the time to the delayed peak, the major cellular phenotype of BP neurons, in HC neurons. Number of subjects: HC=3; HC+CaVC-pep=3; BP=2. Number of cells: HC=37, HC+CaVC-pep=32; BP=31 (Figure 22C).
[0145] (III) Candidate compounds that support the proof of concept (POC) and clinical applicability (translatability) of this discovery.
[0146] In our original submission, we used Uno as the compound for POC. At the cellular level, we also used NS1619. Furthermore, drugs belonging to this category (BK channel activators) include Rottlerin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
[0147] In addition, estramustine was also used as a novel class for POCs in this supplemental data submission. This can be classified as a regulator of protein-protein interactions between VDCC / CaV1.2 and BK channels. This includes estradiol, chlormethine, vinblastine, paclitaxel, ixabepyrone, eruleada, bicalutamide, casodex, leuprolide, zytiga, xtandi, eruleada, eligard, and NSC-639829.
[0148] (summary)
[0149] By performing a comprehensive cellular phenotype / clinical feature correlation analysis using neurons derived from bipolar disorder patients, we initially proposed that attenuation of the VDCC / CaV1.2 and BK channel protein-protein interaction, accompanied by a decrease in BK-dependent potassium outward current—a reflection of reduced BK function—results in a "delay in the time to the calcium peak after neuronal activation," and that this delay is specifically associated with mood change sensitivity in patients. Our new data show that, in addition to BK channel activators, interventions on protein-protein interactions are also effective in improving the clinically relevant calcium cellular phenotype. These new findings further enhance the proof-of-concept and clinical applicability. Furthermore, we provide new data that strengthen the concept of a novel animal model associated with mood change in bipolar disorder (a BK het model with mild sleep deprivation). This disorder is known to involve abnormal function in the mPFC. Our new data further support the possibility that mPFC-mediated behavioral changes in a mouse model with impaired BK (a major molecule in bipolar disorder-related cellular deficiencies) could serve as a good model for mood change in bipolar disorder. In fact, the BK channel activator Uno is effective in both cell and animal models. We are in the final stages of a proof-of-concept (POC) trial to determine whether estramustin is effective in both cell and animal models.
[0150] The data indicate the presence of behavioral change (abrupt behavioral change) in addition to fasting behavior (FST). In contrast, one behavior without behavioral change (OFT) is observed. SST is mediated by the medial prefrontal cortex (mPFC), which is also described herein. OFT is not mediated by the mPFC. These results suggest that behavioral change in the modeling of bipolar disorder is summarized in relation to a noteworthy molecular mechanism (BK channel affected by CaV1.2) as an mPFC-mediated behavioral program associated with sleep deprivation.
[0151] Furthermore, the data define compounds that can bioinformatically intervene in this disease process. We have demonstrated, through molecular intervention data, evidence that certain drugs can treat the pathophysiology of the disease at the cellular level. These indicate that there are two levels of drug intervention in this mechanism: one is by regulating BK function, and the other is by regulating protein-protein interactions, as shown in this embodiment. In addition, direct molecular intervention data supporting this second point are also provided.
[0152] This data also supports the use of the compounds described herein in combination with currently used but inadequate medications. While second-generation antipsychotics are used for bipolar disorder, they are not always sufficiently effective; therefore, the addition of these drugs can lead to more effective improvement, as shown here.
[0153] (Additional data)
[0154] This example demonstrates the potential usefulness of unoprostone (Uno), a BK channel agonist or activator, as a combination therapy with second-generation antipsychotics [e.g., olanzapine (Olz)]. Olz alone is insufficient to improve the cellular deficiency (Ca deficiency) of interest in patients with lithium-resistant bipolar disorder. However, adding Uno to Olz can adequately improve the cellular deficiency of interest.
[0155] Figure 23: Uno as a combination therapy option: Case report. The graph below shows Ca obtained from iN cells derived from a patient with proline-rich transmembrane protein 2 (PRRT2) mutations and clinically diagnosed with bipolar disorder. 2+ The signal transduction data is shown. Ctl represents iN cells derived from a healthy individual, while FAM0002 represents the patient themselves, and the data is obtained from the patient's iN cells. Olz (10 μM) represents FAM0002 iN cells treated with olanzapine (10 μM) for 7 days. Olz + Uno (2 nM) represents FAM0002 iN cells treated with these combined drugs for 7 days.
[0156] In certain embodiments, the disclosure involves contacting cells with a calcium-activated big potassium (BK) channel activator and / or a compound that alters the interaction between CaV1.2 and the BK protein, thereby increasing the Ca in the cells. 2+ This provides a method for altering signal transduction.
[0157] In this specification, the terms “calcium signaling” or “calcium signaling cascade” refer to a series of molecular and biophysical events that use calcium ions to link extracellular stimuli to intracellular responses, including cytoplasmic Ca 2+ It transmits and regulates cellular processes using an increase in Ca as a signal. Calcium ions are Ca 2+ Calcium is released from intracellular organelles that store it, or it enters the cell through the cell membrane. In excitable cells (e.g., nerve cells), the initial chemical stimulus leads to membrane excitation, which activates the calcium signaling pathway. There are at least three basic mechanisms for regulated calcium ion influx across the cell membrane. These are voltage-gated Ca 2+ This includes the action of channels, ligand-gated channels, and capacitive calcium ion influx processes.
[0158] Calcium-activated potassium channels (KCa channels) are a family of ion channels that link changes in intracellular calcium concentration to hyperpolarization of the cell membrane. KCa channels are activated by an increase in cytoplasmic calcium and, in response to an action potential, Ca 2+ When permeable channels open, or when Ca is released from the endoplasmic reticulum 2+ This can occur when potassium is released. One of the two types of KCa channels, the calcium-activated big potassium channel (BK), also known as the high-conductivity calcium-activated potassium channel, is activated under dual regulation by both calcium and membrane potential (membrane depolarization).
[0159] CaV1.2 is a voltage-gated L-type calcium channel that plays a crucial role in many physiological and neurological processes, including brain function. CaV1.2 is the primary calcium channel in nerve cells, contributing to the conversion of electrical signals into calcium signals. This enables intracellular communication, which is essential for learning and memory. Calcium-activated potassium (BK) channels and CaV1.2 channels interact in various ways, including the association of BKα and BKβ subunits 2 and 4 with CaV1.2. 2+ Activation of BK channels by influx shortens the action potential duration and promotes rapid hyperpolarization potential, Ca 2+ It shortens inflow time and restricts neurotransmitter release. CaV channel activation modifies the voltage-dependence, current amplitude, and dynamics of BK channel activation, resulting in functional diversity of BK that depends on the CaV channel expression pattern. The current-voltage relationship of K+ current mediated by BK channels depends on the co-expressed CaV channel subtype.
[0160] In this specification, "Ca 2+"Alterations in signaling" refer to altering or modifying calcium transients, decay, concentration, time to peak, release rate, transient amplitude, or function, or altering how cells utilize calcium to regulate their activity, resulting in a state different from the original. Essentially, it describes a variation of calcium signaling from its physiological, typical, initial, or "normal" form. Alterations in calcium signaling due to contact with a compound include shortening or lengthening the time it takes for intracellular calcium transients to reach peak compared to the time to calcium peak in cells before contact with the compound, or compared to cells not contacted with the compound. Lengthening or shortening of the time to calcium peak includes increases or decreases of at least approximately 1% to 99%, e.g., approximately 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or greater, compared to the time to calcium peak in cells before contact with the compound. In some embodiments, the time to the calcium peak is delayed or shortened within the cell.
[0161] In some embodiments, Ca 2+ Changes in signal transduction include intracellular Ca 2+This includes normalization of the signaling cascade. In this specification, “normalization of calcium signaling” includes, but is not limited to, reducing the time to peak of the calcium transient to a level equivalent to the time to peak of the calcium transient in a reference cell, or increasing the peak amplitude of the calcium transient to a level equivalent to the peak amplitude of the calcium transient in a reference cell. “Reference cell” here refers to a cell that has not been in contact with the compound. The time to peak of the calcium transient is reduced by at least approximately 1% to 99%, for example, approximately 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, or more, compared to the time to the corresponding calcium peak in the cell before contact with the compound. For example, the amplitude of the calcium transient can be increased by at least 0.5 times compared to the calcium transient amplitude in the cell before contact with the compound. The amplitude of the calcium transient can be increased by at least 1 time compared to the calcium transient amplitude in the cell before contact with the compound. The calcium transient amplitude can be increased by at least 1.5 times compared to the calcium transient amplitude of cells before contact with the compound. The calcium transient amplitude can be increased by at least 3 times compared to the calcium transient amplitude of cells before contact with the compound. The calcium transient amplitude can be increased by at least 5 times compared to the calcium transient amplitude of cells before contact with the compound. The calcium transient amplitude can be increased by at least 10 times compared to the calcium transient amplitude of cells before contact with the compound.
[0162] A "signaling cascade" refers to any of the molecular and biophysical events that occur in the intracellular calcium signaling pathway, from an external stimulus to an intracellular response.
[0163] In some embodiments, changes in Ca2+ signaling include correction of intracellular Ca2+ signaling deficiencies. In this specification, “Ca2+ signaling deficiency” refers to a breakdown in Ca2+ signaling, which is the process that links external stimuli with intracellular responses.
[0164] In some embodiments, Ca2+ signaling deficiency manifests as a delay in the time to the calcium peak after cell activation.
[0165] In this specification, "time to calcium peak" refers to the parameter that measures the time it takes for the calcium transient to reach its peak. The time to the calcium peak after nerve cell activation varies depending on the type and condition of the nerve cell. After nerve cell activation, intracellular calcium concentration ([Ca 2+ ]i) The reference value gradually increases and reaches a plateau after current generation. In some embodiments, the time to peak may be delayed by at least about 1% to 99%, e.g., about 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, or more, compared to the time to the corresponding peak in the reference cell. In some embodiments, the time to the calcium peak is delayed within the cell.
[0166] In some embodiments, Ca 2+ The changes in signaling include a reduction in the time to the calcium peak after cell activation. The time to the calcium peak can be reduced by at least about 1% to 99%, for example, about 1%, 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and 95%, compared to the time to the corresponding calcium peak in cells before contact with the compound.
[0167] In some embodiments, shortening the time to the calcium peak after cell activation involves Ca 2+This includes increased intracellular BK channel function and / or CaV1.2-BK protein interaction compared to cells without signaling deficiencies.
[0168] In some embodiments, BK channel function may increase by at least 0.5 times compared to intracellular BK channel function before contact with the compound. BK channel function may increase by at least 1 time compared to intracellular BK channel function before contact with the compound. BK channel function may increase by at least 1.5 times compared to intracellular BK channel function before contact with the compound. BK channel function may increase by at least 3 times compared to intracellular BK channel function before contact with the compound. BK channel function may increase by at least 5 times compared to intracellular BK channel function before contact with the compound. BK channel function may increase by at least 10 times compared to intracellular BK channel function before contact with the compound.
[0169] The intracellular CaV1.2-BK protein interaction may increase by at least 0.5 times compared to the intracellular CaV1.2-BK protein interaction before contact with the compound. The intracellular CaV1.2-BK protein interaction may increase by at least 1 time compared to the intracellular CaV1.2-BK protein interaction before contact with the compound. The intracellular CaV1.2-BK protein interaction may increase by at least 1.5 times compared to the intracellular CaV1.2-BK protein interaction before contact with the compound. The intracellular CaV1.2-BK protein interaction may increase by at least 3 times compared to the intracellular CaV1.2-BK protein interaction before contact with the compound. The intracellular CaV1.2-BK protein interaction may increase by at least 5 times compared to the intracellular CaV1.2-BK protein interaction before contact with the compound. Intracellular CaV1.2-BK protein interactions can increase by at least 10 times compared to intracellular CaV1.2-BK protein interactions before contact with the compound.
[0170] "BK channel activator" means any compound that opens a BK channel. In some embodiments, the BK channel activator is a BK channel agonist. In some embodiments, the BK channel agonist includes unoprostone, unoprostone derivatives, 1-(2'-hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone (also known as NS1619), benzimidazolones or their derivatives, and combinations thereof. Other BK channel activators and / or agonists known to those skilled in the art may also be used in the methods of the present disclosure. For example, in one embodiment, the BK channel agonist is arachidonic acid, cytochrome P450 metabolites such as epoxygenase and lipoxygenase, docosahexaenoic acid, 17β-estradiol, tamoxifen, andrast, zonisamide, chlorzoxazone, cilostazol, human β-defensin 2, Cym04, N'-[3,5-bis(trifluoromethyl)phenyl]-N-[4-bromo-2-(2H-tetrazole-5-yl-phenyl)]thiourea (also known as NS11021), bis-(1,3-dibutylbarbiturate) This includes rimethine oxonol, 5-[(4-bromophenyl)methyl]-2-thiazoleamine (also known as NS19504), (3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-2H-indole-2-one (also known as BMS204352), 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinoline-2(1H)-one (also known as BMS-223131), and combinations thereof. Without being constrained by theory, compounds containing thiourea, tetrahydroquinoline, terpenes, and benzofreundol are thought to be other BK channel activators.Examples of BK channel activators include docosahexaenoic acid, unoprostone (Uno), unoprostone derivatives, 1-(2'-hydroxy-5'-trifluoromethylphenyl)-5-trifluoromethyl-2(3H)-benzimidazolone (also known as NS1619), benzimimidazolone derivatives or their derivatives, Lottrelin, DHS-I, Cym04, BMS191011, MaxiPost, CyPPA, 1-EBIO, GoSlo SR 5-69, GW542573X, NS11021, and SKA. 31, arachidonic acid, cytochrome P450 metabolites such as epoxygenase and lipoxygenase, docosahexaenoic acid, 17β-estradiol, tamoxifen, andlast, zonisamide, chlorzoxazone, cilostazol, human β-defensin 2, Cym04, N'-[3,5-bis(trifluoromethyl)phenyl]-N-[4-bromo-2-(2H-tetrazole-5-yl-phenyl)]thiourea (also known as NS11021), bis-(1,3-dibutylbarbiturate)trimethine oxonol, 5-[ Examples include, but are not limited to, (4-bromophenyl)methyl]-2-thiazoleamine (also known as NS19504), (3S)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-1,3-dihydro-6-(trifluoromethyl)-2H-indole-2-one (also known as BMS204352), 4-(5-chloro-2-hydroxyphenyl)-3-(2-hydroxyethyl)-6-(trifluoromethyl)-quinoline-2(1H)-one (BMS-223131), and combinations thereof.
[0171] In some embodiments, the BK channel agonist is selected from the group consisting of unoprostone (Uno), NS1619, Rottrelin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
[0172] In one embodiment, the BK Channel agonist is Uno.
[0173] Uno (also known as INN) is a prostaglandin analog approved for the treatment of glaucoma and ocular hypertension.
[0174] In another embodiment, the BK channel agonist is NS1619.
[0175] In this specification, “CaV1.2-BK protein interaction” refers to the physical contact or specific proximity between CaV1.2 and BK channels that is important for calcium signaling induced by CaV1.2 and BK channels. Both calcium voltage-gated channels and BK channels are present in nerve cells and interact in various ways to regulate cellular activity. CaV1.2 and BK channels interact primarily through physical proximity, with local calcium influx from CaV1.2 directly activating nearby BK channels, which essentially function as “calcium sensors” to regulate membrane potential by rapidly counteracting depolarization through potassium efflux. This interaction occurs through the formation of densely clustered nanodomain signaling complexes, enabling efficient calcium signaling between the two.
[0176] In some embodiments, compounds that alter the interaction between CaV1.2 and BK protein are selected from the group consisting of estramustine (EM), estradiol, chlormethine, vinblastine, paclitaxel, ixabepyrone, erlead, bicalutamide, casodex, thiourea, tetrahydroquinoline, terpenes, benzofreundole, leuprolide, zytiga, xtandi, erlead, eligard, NSC-639829, and CaV1.2 C-terminal peptide (CaVC-pep).
[0177] In one embodiment, the compound that alters the CaV1.2-BK protein interaction is EM. EM is an approved investigational antitumor agent used for the palliative management of metastatic and / or advanced prostate cancer. EM is a combination of two drugs: estrogen and mechloretamine.
[0178] In another embodiment, EM shortens the time to the intracellular calcium peak after cell activation.
[0179] In another embodiment, the compound that alters the interaction between CaV1.2 and the BK protein is CaVC-pep.
[0180] The C-terminus of the CaV1.2 channel is a cleavable peptide, resulting in the formation of a cleaved channel and a cytoplasmic fragment. The C-terminal fragment is a 14-amino acid peptide located at the C-terminus (amino acids 2106-2120) of CaV1.2. The C-terminus of CaV1.2 plays a role in maintaining intracellular calcium homeostasis and influencing multiple cellular processes.
[0181] In this specification, the terms “peptide,” “polypeptide,” and “protein” are used interchangeably and refer to any chain of at least two amino acids linked by covalent bonds. In this specification, a protein may refer to the entire amino acid sequence or a portion thereof that codes for a full-length protein. A “protein-coding sequence” or a sequence that “codes” a particular polypeptide or peptide is a nucleic acid sequence that, when placed under appropriate regulatory conditions, is transcribed (for DNA) and translated (for mRNA) in vitro or in vivo to become a polypeptide. The boundaries of a coding sequence are determined by a start codon at the 5' (amino) end and a translation termination codon at the 3' (carboxyl) end. Coding sequences include, but are not limited to, prokaryotic or eukaryotic mRNA-derived cDNA, prokaryotic or eukaryotic genomic DNA sequences, and synthetic DNA sequences. The transcription termination sequence is usually located on the 3' side of the coding sequence.
[0182] In another embodiment, CaVC-pep extends the time to the intracellular calcium peak after cell activation.
[0183] The compounds described herein are intracellular Ca 2+It is used to alter signal transduction. In some embodiments, the cells are nerve cells. In various embodiments, nerve cells are present within the subject.
[0184] In yet another embodiment, the nerve cells are glutamatergic nerve cells. In this specification, “glutamatergic nerve cells” refers to nerve cells that produce glutamate, the major excitatory neurotransmitter in the central nervous system (CNS). Glutamatergic nerve cells are widely distributed in the CNS, and it is estimated that more than half of brain synapses release glutamate.
[0185] In some embodiments, the nerve cells are CaMKII-positive glutamatergic cells. In this specification, “CaMKII-positive glutamatergic cells” refers to glutamatergic nerve cells expressing calcium / calmodulin-dependent protein kinase II (CaMKII). CaMKII is a protein kinase involved in the regulation of neurotransmission and synaptic plasticity. CaMKII is a marker for glutamatergic pyramidal nerves.
[0186] In many embodiments, the cells are induced neurons (iNs) or induced pluripotent stem cell-derived neurons (iPSCs).
[0187] As further details are provided in the Examples section, the cells used in the methods described herein are either cells from a subject (in vivo application of the methods) or cultured cells (in vitro application of the methods). When applied in an in vitro context, the method claims of the present invention are applicable to nerve cells derived from subjects having mental disorders such as bipolar disorder. Methods for inducing iPSCs from subjects are widely known to those skilled in the art and, simply put, involve reprogramming differentiated cells into stem cells by exposing them to “reprogramming factors” (including transcription factors Oct4(Pou5f1), Sox2, Klf4, and cMyc). This specification includes iPSCs induced from fibroblasts (e.g., obtained from skin biopsies), peripheral blood cells, or renal epithelial cells in urine.
[0188] In certain embodiments, the present disclosure provides a method for treating a mental disorder in a subject, which involves Ca in the subject's cells. 2+ This involves administering a therapeutically effective amount of a compound that normalizes signal transduction to a subject, thereby treating a mental disorder.
[0189] In this specification, “mental disorder” refers to a mental health condition that can have a significant impact on an individual’s thoughts, feelings, moods, and behaviors. Symptoms are more severe than the usual response to unpleasant events and may include distress, functional impairment, and the risk of self-harm. Examples of mental disorders, but not limited to, include anxiety disorders, schizophrenia, major depressive disorder, borderline personality disorder, bipolar disorder, eating disorders, personality disorders, and psychotic disorders.
[0190] In some aspects, mental disorders are characterized by changes in adaptive behavior mediated by the medial prefrontal cortex. Adaptive behavior refers to learned behaviors that reflect an individual's social and practical abilities to meet the demands of daily life. To meet the demands of their environment, each individual must learn a set of skills. Change in adaptive behavior is the process of learning new skills to meet the demands of a changing environment. Changes or deficits in adaptive behavior can be associated with mental health and cognition. The medial prefrontal cortex (mPFC) is a crucial cortical region with diverse cell types and projections that integrates information from multiple cortical regions and aggregates updated information into output structures. The mPFC plays an essential role in cognitive processes, emotional regulation, motivation, and socialization. Deficiencies in the mPFC are found in a variety of neurological and psychiatric disorders, including but not limited to depression, anxiety disorders, schizophrenia, autism spectrum disorder, bipolar disorder, borderline personality disorder, Alzheimer's disease, Parkinson's disease, and addiction.
[0191] In some forms, mental disorders characterized by adaptive behavioral changes mediated by the medial prefrontal cortex include bipolar disorder, schizophrenia, major depressive disorder, borderline personality disorder, anxiety disorders, or combinations thereof.
[0192] The methods described herein rely on the administration of the compounds described herein for the treatment of mental disorders in subjects.
[0193] In this specification, “subject” refers to an individual or patient on whom the method of the present invention is performed. While the subject is human, as those skilled in the art will understand, the subject may also be a non-human animal. Therefore, other animals, namely vertebrates such as rodents (including mice, rats, hamsters, and guinea pigs), domestic animals such as cats, dogs, rabbits, cattle, horses, goats, sheep, pigs, and chickens, as well as primates (including monkeys, chimpanzees, orangutans, and gorillas), are also included in the definition of a subject. In some embodiments, the subject may be a lithium non-reactive or a lithium reactive. In various embodiments, the subject is a lithium non-reactive.
[0194] In this specification, “treatment” is used without distinction from “therapeutic method” or “treatment,” and means (1) a therapeutic action or means that results in the cure, slowing of progression, reduction of symptoms and / or cessation of progression of a diagnosed pathological condition or disorder, and / or (2) a preventive / protective measure. Persons requiring treatment include not only individuals who already have a particular medical disorder, but also those who are likely to eventually develop the disorder (i.e., those who require preventive measures).
[0195] In this specification, terms such as “therapeutic effective dose,” “effective dose,” “therapeutic effective dose,” and “effective dose” refer to the amount of the compound of the present invention that elicits a biological or medical response in a tissue, system, animal, or human, as sought by researchers, veterinarians, physicians, or other clinicians. Generally, the response is an improvement in the patient’s symptoms or a desired biological outcome (e.g., immune activation). Such an amount is Ca 2+ The amount must be sufficient to normalize signaling and treat mental disorders. The effective dose can be determined by the method described herein.
[0196] Therapeutic effects may be objective (i.e., measurable by some test or marker) or subjective (i.e., suggested or felt by the subject, or observed by a physician). Effects envisioned herein include, where appropriate, medical therapeutic effects. The specific dose of a compound to obtain a therapeutic effect administered in accordance with this disclosure will naturally be determined by the specific circumstances surrounding the case, including the compound administered, the route of administration, concomitant use of other active ingredients, the condition being treated, the activity of the specific compound used, the specific composition used, the subject's age, weight, general condition, sex, diet, timing of administration, route of administration, excretion rate of the specific compound, and duration of treatment. The effective dose will be determined by a physician based on the above-mentioned relevant factors and appropriate medical judgment. The therapeutically effective dose of a compound in this disclosure is typically sufficient to achieve a systemic or tissue-effective concentration when administered in a physiologically acceptable excipient composition.
[0197] In this specification, “to treat,” “treated,” or “treatment” means a therapeutic procedure whose purpose is to achieve beneficial or desired clinical outcomes, such as (partially or completely) protection against or delaying the progression of an undesirable physiological condition, disorder, or disease (e.g., reduction or delay of onset), or partial or complete recovery or suppression of a decline in an abnormal parameter, value, function, or outcome. For the purposes of this disclosure, beneficial or desired clinical outcomes include relief of symptoms, reduction of the degree, intensity, or rate of progression of a condition, disorder, or disease, stabilization of a condition, disorder, or disease (i.e., no worsening), delay of onset or progression of a condition, disorder, or disease, improvement of a condition, disorder, or disease, or remission (partial or complete), which do not necessarily result in immediate relief of clinical symptoms, but may also include enhancement or improvement of a condition, disorder, or disease. Treatment aims to elicit a clinically significant response without excessive side effects. Treatment also includes extending survival compared to no treatment.
[0198] "Pharmacopoeia-acceptable" means molecular entities and compositions that are generally considered safe and non-toxic. In particular, pharmaceutically acceptable carriers, diluents, or other excipients used in the pharmaceutical compositions of this disclosure are physiologically tolerable, compatible with other components, and do not typically cause allergic reactions or similar undesirable reactions (e.g., stomach upset, dizziness, etc.) when administered to a subject. In some embodiments, "pharmaceutically acceptable" as used herein means approved by a federal or state regulatory agency or listed in the United States Pharmacopeia or other generally accepted pharmacopoeias for use in animals, particularly humans. "Pharmacopoeia-acceptable salt" as used herein includes salts of the compounds of this disclosure that are safe and effective for use in mammals and have the desired biological activity. Pharmaceutically acceptable salts include salts of acidic or basic groups present in the compounds of this disclosure or compounds identified according to the methods of this disclosure.
[0199] As used herein, “therapeutic” means an agent used to treat, counteract, improve, defend against, or improve an undesirable condition or disease in a subject.
[0200] The terms “administer” or “to administer” should be understood to mean providing a therapeutically effective amount of the pharmaceutical composition to a subject in need of treatment. “To administer,” when used in conjunction with the compounds of this disclosure, means to directly administer the compound to a target tissue or to administer the compound systemically or topically to a patient or other subject. The treatments disclosed herein include intravenous, auricle (otology), buccal mucosa, conjunctiva, skin, dental, electroosmosis, intracervical, intranasal sinus, intratracheal, enteral, epidural, extraamniotic, extracorporeal, hemodialysis, infiltration, intrastitium, intraperitoneal, intraamniotic, intraarterial, intraarticular, intrabiliary, intrabronchial, intrasacral, intracardiac, intracardiac, intracardiac, intracartilage, intracavitary, intracorpus cavernosum, intrabody cavity, intracerebral, intraventricular, intracisional, intracorneal, intradental, intracoronal, intraarterial, intrasacral, intracorpus cavernosum, intradermal, intradiscal, intracanal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intraileal, intralesional, intraluminal, intravascular, intrabone marrow, intrameningeal, intramuscular, intraocular, intraocular, intraovarian, intrapericardial, intraperitoneal, intrapleural, intraprostate, intralungal, intranasal sinus, spinal The drug is administered to the subject via intramedullary, synovial, tendonal, testicular, subarachnoid, intrathoracic, intratubular, intratumoral, intratympanic, intrauterine, intravascular, intravenous, intravenous bolus, intravenous infusion, intraventricular, intrabladder, intravitreous, iontophoresis, perfusion, intralaryngeal, intranasal, transnasogastric, closed dressing, ophthalmic, oral, oropharyngeal, other, parenteral, percutaneous, periarticular, peridural, perineurial, periodontal, rectal, respiratory (inhalation), posterior orbital, soft tissue, subarachnoid, subconjunctival, subcutaneous, sublingual, submucosal, topical, percutaneous, transmucosal, transplacental, transtracheal, transtympanic, ureter, urethral, vaginal administration, and / or any combination of the above administration routes.
[0201] In some embodiments, Ca in the cells of the subject 2+ Compounds that normalize signal transduction are those that alter the interaction between calcium-activated big potassium (BK) channel activators and / or CaV1.2 and the BK protein.
[0202] In some embodiments, a BK channel activator is a BK channel agonist.
[0203] In some embodiments, the BK channel agonist is selected from the group consisting of Uno, NS1619, Rottlerin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
[0204] In one embodiment, the BK channel agonist is Uno. In several embodiments, the BK channel agonist is Uno or a structural analogue thereof.
[0205] In another embodiment, the BK channel agonist is NS1619.
[0206] In some embodiments, compounds that alter the interaction between CaV1.2 and BK protein are selected from the group consisting of estramustine (EM), estradiol, chlormethine, vinblastine, paclitaxel, ixabepyrone, eruleada, bicalutamide, casodex, leuprolide, zytiga, xtandi, eruleada, eligard, and NSC-639829.
[0207] In one embodiment, the compound that alters the interaction between CaV1.2 and the BK protein is EM.
[0208] In a further embodiment, EM increases the interaction between CaV1.2 and BK protein within cells.
[0209] In some aspects, the cell is a nerve cell.
[0210] In some embodiments, nerve cells are glutamatergic nerve cells.
[0211] In certain embodiments, nerve cells are CaMKII-positive glutamatergic cells.
[0212] In certain embodiments, this disclosure relates to Ca in the cells of the subject. 2+ The present invention provides a method for treating a subject's bipolar disorder, comprising administering a therapeutically effective amount of a compound that normalizes signal transduction to the subject.
[0213] Bipolar disorder is a mental disorder characterized by extreme fluctuations in mood, energy levels, activity levels, and concentration. These fluctuations make it difficult to perform everyday tasks and are more severe than typical mood swings. BP is characterized by behavioral abnormalities, including but not limited to manic episodes, depressive episodes, hypomania, delusions, hallucinations, thought disturbances, insomnia, increased need for sleep, and thoughts of death or suicide.
[0214] In some aspects, treatment for bipolar disorder involves reducing medial prefrontal cortex (mPFC)-related behavioral abnormalities in subjects in response to stressors.
[0215] In some embodiments, mPFC-related behavioral abnormalities include behavioral changes, mood changes, and / or adaptive stress responses.
[0216] In this specification, the terms “behavioral shift” or “mood shift” refer to a rapid shift from one mood state to another, such as a transition from depression to mania or hypomania, or vice versa. This is a core feature of BPD that distinguishes it from other mental disorders. Patients with BP may exhibit a variety of stress responses, including increased cognitive reactivity, heightened emotional reactivity, and vulnerability to stress.
[0217] In some embodiments, Ca 2+ Compounds that normalize the signaling cascade are those that alter the interaction between calcium-activated big potassium (BK) channel activators and / or CaV1.2 and BK proteins.
[0218] In some embodiments, a BK channel activator is a BK channel agonist.
[0219] In some embodiments, the BK channel agonist is selected from the group consisting of unoprostone (Uno), NS1619, Rottrelin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
[0220] In one embodiment, the BK Channel agonist is Uno.
[0221] In another embodiment, the BK channel agonist is NS1619.
[0222] In some embodiments, compounds that alter the interaction between CaV1.2 and BK protein are selected from the group consisting of estramustine (EM), estradiol, chlormethine, vinblastine, paclitaxel, ixabepyrone, eruleada, bicalutamide, casodex, leuprolide, zytiga, xtandi, eruleada, eligard, and NSC-639829.
[0223] In one embodiment, the compound that alters the interaction between CaV1.2 and the BK protein is EM.
[0224] In some embodiments, EM increases the interaction between aV1.2 and BK protein within cells.
[0225] In some aspects, the cell is a nerve cell.
[0226] In some embodiments, nerve cells are glutamatergic nerve cells.
[0227] In some embodiments, nerve cells are CaMKII-positive glutamatergic cells.
[0228] In yet another embodiment, the nerve cells are mPFC CaMKII-positive glutamatergic cells.
[0229] In certain embodiments, the Disclosure provides a method for modulating mood changes, behavioral changes, and / or adaptive stress responses in a subject, which includes Ca in the subject's cells. 2+ This involves administering compounds that normalize signaling to subjects, thereby modulating their mood changes, behavioral changes, and / or adaptive stress responses.
[0230] In some embodiments, mood changes, behavioral changes, and / or modulation of adaptive stress responses include mitigating medial prefrontal cortex (mPFC)-related behavioral abnormalities in subjects responding to stressors.
[0231] In some embodiments, Ca 2+ Compounds that normalize the signaling cascade are those that alter the interaction between calcium-activated big potassium (BK) channel activators and / or CaV1.2 and BK proteins.
[0232] In some embodiments, a BK channel activator is a BK channel agonist.
[0233] In some embodiments, the BK channel agonist is selected from the group consisting of unoprostone (Uno), NS1619, Rottrelin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
[0234] In one embodiment, the BK Channel agonist is Uno.
[0235] In other embodiments, the BK channel agonist is NS1619.
[0236] In some embodiments, compounds that alter the interaction between CaV1.2 and BK protein are selected from the group consisting of estramustine (EM), estradiol, chlormethine, vinblastine, paclitaxel, ixabepyrone, eruleada, bicalutamide, casodex, leuprolide, zytiga, xtandi, eruleada, eligard, and NSC-639829.
[0237] In one embodiment, the compound that alters the interaction between CaV1.2 and the BK protein is EM.
[0238] In yet another embodiment, EM increases the interaction between aV1.2 and BK protein within the cell.
[0239] In some aspects, the cell is a nerve cell.
[0240] In some embodiments, nerve cells are glutamatergic nerve cells.
[0241] In yet another embodiment, the nerve cells are CaMKII-positive glutamatergic cells.
[0242] In some embodiments, the above embodiments further include administering treatment for a mental disorder to the subject.
[0243] Mental illness can be treated with a variety of options, including medications. In this specification, the term “treatment of mental illness” includes all treatments that can be administered to a subject for the treatment or management of a mental illness. Non-exclusive examples of treatments for mental illness include antidepressants, antipsychotics, mood stabilizers, anticonvulsants, psychotherapy, and alternative therapies.
[0244] In some aspects, the treatment of mental illness is the treatment of bipolar disorder, schizophrenia, major depressive disorder, borderline personality disorder, anxiety disorders, or combinations thereof.
[0245] In some aspects, treatment for mental illness includes psychotherapy, medication, or a combination thereof.
[0246] In this specification, “therapeutic agent” means a substance, including an active agent or active ingredient, used to treat, prevent, or manage a disease. The term “agent” includes, but is not limited to, small molecules (including small molecules that do not have optimal cell permeability), lipids, nucleosides, nucleotides, nucleic acids, polynucleotides, oligonucleotides, antibodies, toxins, negatively charged polymers and other polymers, such as proteins, peptides, hormones, carbohydrates, or polyamines. Therapeutic agents may be natural or synthetic and are used to cure diseases, alleviate or eliminate symptoms, and improve quality of life.
[0247] In some embodiments, the therapeutic agent includes mood stabilizers, anticonvulsants, antipsychotics, or combinations thereof.
[0248] As used herein, "mood stabilizer" refers to a group of psychiatric medications used for the treatment of mood disorders characterized by extreme and persistent mood swings, such as bipolar disorder. Non-limiting examples of mood stabilizers include lithium, valproic acid, lamotrigine, carbamazepine, gabapentin, and aripiprazole. As used herein, "anticonvulsant" refers to an antiepileptic or antiseizure agent, which is a group of drugs used for the treatment of seizures and other diseases such as BP. Examples of anticonvulsants include, but are not limited to, brivaracetam (Briviact®), cannabidiol oral solution (Epidiolex®), carbamazepine, cenobamate (Xcopri), clobazam (Onfi® and Sympazan™), and clonazepam (Klonopin). As used herein, "antipsychotic" refers to a neuroleptic or major tranquilizer, which is a group of drugs used for the treatment of psychotic symptoms. Non-limiting examples of antipsychotics include chlorpromazine (Thorazine), fluphenazine (Prolixin, Permitil), haloperidol (Haldol), loxapine (Loxapac), perphenazine (Trilafon), pimozide (Orap), thiothixene (Navane), trifluoperazine (Stelazine), zuclopenthixol (Clopixol), aripiprazole (Abilify, Aristada), asenapine (Secuado, Saphris), brexpiprazole (Rexulti), cariprazine (Vraylar), clozapine (Clozaril, Versacloz), iloperidone (Fanapt), lumateperone (Caplyta), lurasidone (Latuda), olanzapine (Zyprexa, Lybalvi, Symbyax), quetiapine (Seroquel), paliperidone (Invega), pimavanserin (Nuplazid), risperidone (Perseris, Risperdal), and ziprasidone (Geodon).
[0249] In some embodiments, the mood stabilizer is lithium.
[0250] In some embodiments, the therapeutic agent for psychiatric disorders is olanzapine.
[0251] Olanzapine is an antipsychotic agent used for the treatment of adults and adolescents 13 years of age and older with schizophrenia or bipolar I disorder. For bipolar I disorder, it is used (i) alone for manic or mixed episodes, or in combination with lithium or valproic acid, and (ii) in combination with fluoxetine for depressive episodes in individuals 10 years of age and older. For treatment-resistant depression, olanzapine is used in combination with fluoxetine.
[0252] In certain embodiments, the present disclosure provides a method of identifying a compound as a candidate therapeutic agent for bipolar disorder, which comprises (i) administering the candidate compound to a subject, wherein the subject exhibits haploinsufficiency of calcium-activated big potassium (BK) channels, (ii) exposing the subject to a mild stressor, thereby inducing a behavioral response, (iii) identifying the candidate compound as the candidate therapeutic agent when a behavioral alteration to the candidate compound is induced, as compared to a control behavioral response to the candidate compound in a subject that does not exhibit BK channel haploinsufficiency.
[0253] In some embodiments, the mild stressor is short-term sleep deprivation. In some embodiments, the subject is a genetically modified non-human animal. In various embodiments, the animal is a mouse. In some embodiments, the method further comprises subjecting the subject to a forced swimming test before and after exposure to the mild stressor. In some embodiments, inducing the behavioral response comprises altering the immobility time of the subject in the forced swimming test.
[0254] In this specification, subjects exhibiting "haploinsufficiency of BK channels" refer to the genetically modified animal model of bipolar disorder described herein. Using this model, behavioral changes are demonstrated in genetically modified mice conferring SD. No behavioral changes occur when the same stressor, SD, is administered to wild-type mice (WT). Modulation of BK channels is sufficient only in excitatory neurons of the medial prefrontal cortex, indicating the neurons / brain regions involved in this phenotype. Furthermore, this pathological phenotype was observed to be completely rescued by administration of the BK channel activators Uno and NS1619.
[0255] The presence or absence of behavioral change can be determined using a forced swimming test. For example, genetically modified non-human animals exhibit different behaviors in a forced swimming test before and after exposure to a mild stressor, indicating behavioral change. If behavioral change is prevented by administration of a candidate compound, the candidate compound is a promising candidate treatment for bipolar disorder.
[0256] The mouse models disclosed herein can serve as models for BP patients, and rescue of this pathological phenotype demonstrates that therapeutic agents may be used to treat bipolar disorder. The mouse models and methods disclosed herein may, in certain embodiments, be used for the development and screening of therapeutic agents for BP.
[0257] Although the present invention has been described with reference to the above embodiments, it should be understood that modifications and variations are included within the spirit and scope of the invention. Accordingly, the present invention is limited only by the appended claims.
Claims
1. A method for evaluating the efficacy of a composition in the treatment of bipolar disorder, comprising: preparing a genetically modified non-human animal exhibiting BK channel haploinsufficiency; administering the composition to the genetically modified non-human animal; exposing the genetically modified non-human animal to a mild stressor; and determining whether the genetically modified non-human animal undergoes a behavioral change.
2. The method according to claim 1, wherein the mild stressor is a short period of sleep deprivation.
3. The method according to claim 1, further comprising subjecting the genetically modified non-human animal to a forced swimming test before and after exposing the genetically modified non-human animal to the mild stressor.
4. A method for treating bipolar disorder in a subject requiring treatment, comprising administering a therapeutically effective dose of a BK channel agonist to the subject.
5. The method according to claim 4, wherein the BK channel agonist includes unoprostone, unoprostone derivatives, NS1619, benzimidazolones or their derivatives, and combinations thereof.
6. The method according to claim 4, wherein the subject is a lithium non-reactive.
7. The method according to any one of claims 2 to 4, wherein the non-human animal is a mouse.
8. A method for evaluating the mechanism of bipolar disorder in human-derived neurons, comprising providing a mechanism that causes mood swings, attenuates the protein-protein interaction between CaV1.2 and BK, and leads to a deficiency in calcium signaling.
9. A method for altering intracellular calcium (Ca2+) signaling, comprising contacting the cells with a calcium-activated big potassium (BK) channel activator and / or a compound that alters the interaction between CaV1.2 and the BK protein, thereby altering the intracellular Ca2+ signaling.
10. The method according to claim 9, wherein altering Ca2+ signaling is equivalent to normalizing intracellular Ca2+ signaling.
11. The method according to claim 9, wherein altering Ca2+ signaling is to correct the deficiency of intracellular Ca2+ signaling.
12. The method according to claim 11, wherein the deficiency in Ca2+ signaling is a delay in the time to the calcium peak after cell activation.
13. The method according to claim 12, wherein altering Ca2+ signaling is a means of shortening the time to the calcium peak after cell activation within the cell.
14. The method according to claim 13, wherein shortening the time to the calcium peak after cell activation within the cell is to increase the BK channel function and / or the interaction between CaV1.2 and BK protein in the cell compared to the BK channel function and the interaction between CaV1.2 and BK protein in cells without Ca2+ signaling deficiency.
15. The method according to claim 9, wherein the BK channel activator is a BK channel agonist.
16. The method according to claim 15, wherein the BK channel agonist is selected from the group consisting of unoprostone (Uno), NS1619, Rottrelin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
17. The method according to claim 15, wherein the BK channel agonist is Uno.
18. The method according to claim 15, wherein the BK channel agonist is NS1619.
19. The method according to claim 9, wherein the compound that alters the interaction between CaV1.2 and BK protein is selected from the group consisting of estramustine (EM), estradiol, chlormethine, vinblastine, paclitaxel, ixabepylone, erlead, bicalutamide, casodex, leuprolide, zytiga, xtandi, erlead, eligard, NSC-639829, and CaV1.2 C-terminal peptide (CaVC-pep).
20. The method according to claim 19, wherein the compound that alters the interaction between CaV1.2 and BK protein is EM.
21. The method according to claim 20, wherein EM shortens the time to the calcium peak after cell activation within the cell.
22. The method according to claim 19, wherein the compound that alters the interaction between CaV1.2 and BK protein is CaVC-pep.
23. The method according to claim 22, wherein CaVC-pep extends the time to the calcium peak after cell activation within the cell.
24. The method according to claim 9, wherein the cell is a nerve cell.
25. The method according to claim 24, wherein the nerve cells are glutamatergic nerve cells.
26. The method according to claim 25, wherein the nerve cells are CaMKII-positive glutamatergic cells.
27. A method for treating a mental disorder in a subject, comprising administering to the subject a therapeutically effective amount of a compound that normalizes Ca2+ signaling in the subject's cells, thereby treating the subject's bipolar disorder.
28. The method according to claim 27, wherein the mental disorder is characterized by changes in adaptive behavior mediated by the medial prefrontal cortex.
29. The method according to claim 28, wherein the mental disorder characterized by the adaptive behavioral changes mediated by the medial prefrontal cortex is bipolar disorder, schizophrenia, major depressive disorder, borderline personality disorder, anxiety disorder, or a combination thereof.
30. The method according to claim 27, wherein the compound that normalizes Ca2+ signaling is a calcium-activated big potassium (BK) channel activator and / or a compound that alters the interaction between CaV1.2 and the BK protein.
31. The method according to claim 30, wherein the BK channel activator is a BK channel agonist.
32. The method according to claim 31, wherein the BK channel agonist is selected from the group consisting of unoprostone (Uno), NS1619, Lottrelin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
33. The method according to claim 31, wherein the BK channel agonist is Uno.
34. The method according to claim 31, wherein the BK channel agonist is NS1619.
35. The method according to claim 31, wherein the compound that alters the interaction between CaV1.2 and BK protein is selected from the group consisting of estramustine (EM), estradiol, chlormethine, vinblastine, paclitaxel, ixabepylone, erlead, bicalutamide, casodex, leuprolide, zytiga, xtandi, erlead, eligard, and NSC-639829.
36. The method according to claim 30, wherein the compound that alters the interaction between CaV1.2 and BK protein is EM.
37. The method according to claim 36, wherein the EM increases the interaction between CaV1.2 and BK protein within the cell.
38. The method according to claim 27, wherein the cell is a nerve cell.
39. The method according to claim 39, wherein the nerve cell is a glutamatergic nerve cell.
40. The method according to claim 40, wherein the nerve cells are CaMKII-positive glutamatergic cells.
41. A method for treating bipolar disorder in a subject, comprising administering a therapeutically effective amount of a compound that normalizes Ca2+ signaling in the subject's cells, thereby treating the subject's bipolar disorder.
42. The method according to claim 41, wherein the treatment of bipolar disorder includes reducing medial prefrontal cortex (mPFC)-related behavioral abnormalities in the subject in response to stressors.
43. The method according to claim 42, wherein mPFC-related behavioral abnormalities include behavioral changes, mood changes, and / or adaptive stress responses.
44. The method according to claim 41, wherein the compound that normalizes the Ca2+ signaling cascade is a calcium-activated big potassium (BK) channel activator and / or a compound that alters the interaction between CaV1.2 and the BK protein.
45. The method according to claim 44, wherein the BK channel activator is a BK channel agonist.
46. The method according to claim 45, wherein the BK channel agonist is selected from the group consisting of unoprostone (Uno), NS1619, Lottrelin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
47. The method according to claim 45, wherein the BK channel agonist is Uno.
48. The method according to claim 45, wherein the BK channel agonist is NS1619.
49. The method according to claim 44, wherein the compound that alters the interaction between CaV1.2 and BK protein is selected from the group consisting of estramustine (EM), estradiol, chlormethine, vinblastine, paclitaxel, ixabepyrone, erlead, bicalutamide, casodex, leuprolide, zytiga, xtandi, erlead, eligard, and NSC-639829.
50. The method according to claim 44, wherein the compound that alters the interaction between CaV1.2 and BK protein is EM.
51. The method according to claim 50, wherein the EM increases the interaction between CaV1.2 and BK protein within the cell.
52. The method according to claim 41, wherein the cell is a nerve cell.
53. The method according to claim 52, wherein the nerve cell is a glutamatergic nerve cell.
54. The method according to claim 52, wherein the nerve cells are CaMKII-positive glutamatergic cells.
55. The method according to claim 54, wherein the nerve cells are mPFC CaMKII-positive glutamatergic cells.
56. A method for regulating a subject's mood change, behavior change, and / or adaptive stress response, comprising administering to the subject a compound that normalizes Ca2+ signaling in the subject's cells, thereby regulating the subject's mood change, behavior change, and / or adaptive stress response.
57. The method according to claim 56, wherein the mood change, behavior change, and / or modulation of adaptive stress response comprises reducing mPFC-related behavioral abnormalities in the subject in response to a stressor.
58. The method according to claim 57, wherein the compound that normalizes the Ca2+ signaling cascade is a compound that alters the interaction between a calcium-activated big potassium (BK) channel activator and / or CaV1.2 and the BK protein.
59. The method according to claim 58, wherein the BK channel activator is a BK channel agonist.
60. The method according to claim 59, wherein the BK channel agonist is selected from the group consisting of unoprostone (Uno), NS1619, Rottrelin, BMS191011, BMS204352, BMS223131, GoSlo SR 5-69, LDD175, MaxiPost, NS11021, and NS19504.
61. The method according to claim 59, wherein the BK channel agonist is Uno.
62. The method according to claim 59, wherein the BK channel agonist is NS1619.
63. The method according to claim 58, wherein the compound that alters the interaction between CaV1.2 and BK protein is selected from the group consisting of estramustine (EM), estradiol, chlormethine, vinblastine, paclitaxel, ixabepyrone, erlead, bicalutamide, casodex, leuprolide, zytiga, xtandi, erlead, eligard, and NSC-639829.
64. The method according to claim 58, wherein the compound that alters the interaction between CaV1.2 and BK protein is EM.
65. The method according to claim 64, wherein the EM increases the interaction between CaV1.2 and BK protein within the cell.
66. The method according to claim 56, wherein the cell is a nerve cell.
67. The method according to claim 66, wherein the nerve cells are glutamatergic nerve cells.
68. The method according to claim 66, wherein the nerve cells are CaMKII-positive glutamatergic cells.
69. The method according to any one of claims 27 to 68, further comprising administering treatment for a mental illness to the subject.
70. The method according to claim 69, wherein the treatment for the mental disorder is the treatment for bipolar disorder, schizophrenia, major depressive disorder, borderline personality disorder, anxiety disorder, or a combination thereof.
71. The method according to claim 69, wherein the treatment for the mental disorder includes psychotherapy, a drug, or a combination thereof.
72. The method according to claim 71, wherein the therapeutic agent comprises a mood stabilizer, an anticonvulsant, an antipsychotic, or a combination thereof.
73. The method according to claim 72, wherein the mood stabilizer is lithium.
74. The method according to claim 69, wherein the drug used to treat mental illness is olanzapine.
75. (a) Administering a candidate compound to a subject, wherein the subject exhibits haploinsufficiency of calcium-activated big potassium (BK) channels. (b) Exposing the subject to a mild stressor to induce a behavioral response, and (c) When a change in behavior towards the candidate compound is induced compared to a control behavioral response to the candidate compound in subjects that do not show BK channel haploinsufficiency, the candidate compound is identified as a candidate therapeutic agent. A method for identifying compounds as candidate therapeutic agents for bipolar disorder, including [specific compound name].
76. The method according to claim 75, wherein the mild stressor is a short period of sleep deprivation.
77. The method according to claim 75, wherein the subject is a genetically modified non-human animal.
78. The method according to claim 77, wherein the subject is a mouse.
79. The method according to claim 77, further comprising subjecting the subject to a forced swimming test before and after exposure to a mild stressor.
80. The method according to claim 75, wherein inducing a behavioral response includes changing the immobility time of the subject in the forced swimming test.
81. The method according to any one of the prior claims, wherein the subject is a lithium non-reactive.
82. The method according to any one of the prior claims, wherein the cells are induced nerve cells (iN) or induced pluripotent stem cell-derived nerve cells (iPSC-nerve cells).
